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Involvement of NF κ B pathway in the synthesis of Twist1 in circulating Sezary tumor cells 
B Baroudjan, C Ram-Wolf, F Jean-Louis, A Bensussan, M Bagot and L Michel Dermatology, 
Inserm U976, Paris, France
Sezary syndrome (SZ) is an epidermotropic cutaneous T cell lymphoma (CTCL) characterized by 
lymphoproliferation of memory CD4+ T cells that express specific biomarkers, including the tran-
scription factor Twist1. Cutaneous and blood expression of Twist is correlated with disease stages, 
with detection of Twistin circulating tumor T cells in more than 90% of SZ patients. Beside its 
contribution to the embryonic development, Twist is synthesized by most of the cells of meso-
dermal origin in adults, mainly under the control of NFkB pathway. It has been involved in the 
oncogenic process of carcinomas by promoting epithelial-mesenchymal transition. Since we have 
demonstrated that the NFkB pathway was constitutively activated in tumor cells of SZ patients, 
we aimed to establish whether Twist expression depends on the constitutive activation of NFkB 
pathway in SZ. Gene and protein expression of Twist was quantified in SZ lines and tumor cells of 
SZ patients using qPCR and immunoblot. Downregulation of the NFkB pathway was induced by 
specific inhibitors or dominant negative plasmids. As expected, we detected Twist gene and protein 
expression in cell lines and circulating CD4+T cells of SZ patients, whereas Twist was totally absent 
in control T cells. A decrease in Twist gene expression was observed after NFkB pathway inhibition, 
with a maximum of 60% after 4h in both CTCL cell lines and tumor T cells from patients (n=12). 
The immunoblot analysis showed a sharp reduction of Twist1 expression after NFkB inhibition for 
24h. Downregulation of NFkB pathway by the specific super-repressor ΔnIkBα transfection lead to 
a decrease in Twist expression, as did also Twist siRNA. The specific Twist synthesis by tumor SZ 
cells through the NFkB pathway may also contribute to their resistance to apoptosis, as suggested 
by an increase in tumor cell apoptosis after Twist siRNA transfection. In conclusion, the decrease 
of Twist expression in SZ tumor cells after NFkB pathway inhibition demonstrates the involvement 
of this pathway in Twist synthesis, suggesting that it might be used as a therapeutic target.    
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Dermatological findings of chronic itch in hemodialysis patients: results from GEHIS (German 
Epidemiological Hemodialysis-Itch Study) 
K Hayani, M Weiss and E Weisshaar Dept. of Clinical Social Medicine, Environmental and 
Occupational Dermatology, University Hospital Heidelberg, Heidelberg, Germany
Chronic itch (CI) in hemodialysis (HD) patients still is a neglected problem. A representative 
cross-sectional study was conducted in 25 randomly selected dialysis units in Germany with the 
aim to assess epidemiological and clinical data of CI. HD patients suffering from CI received a 
dermatological examination by a dermatologist in order to assess the dermatoses as well as the 
International Forum for the Study of Itch (IFSI) classification in this group of patients. The Clinical 
characteristics of itch as well as the severity of CI were assessed using a visual analogue scale (VAS). 
860 HD patients were included into GEHIS. 167 (25.2%) of these patients with presented with CI. 
80.4% had the skin phototype (II). 89.3% suffered from xerosis cutis, 47% from onychodystrophia 
and 33.9% from atrophy of the skin. 32.1% showed actinic skin damage. 9.5% had a clinical picture 
consistent with prurigo nodularis. CI correlated significantly with two sites of the body, the chest 
and the lower limb. Using the IFSI classification, 41.3% suffered from CI without any skin lesions 
(corresponding to IFSI II), 38.9% had secondary scratch lesions (IFSI III), 19,8% showed a specific 
efflorescence (IFSI I). No significant correlation between the duration of HD (first required HD 
treatment) and the severity of CI could be found. There was a correlation between the duration of 
HD and the IFSI type where it could be stated that, the longer the duration of the HD is, the most 
frequent the diagnosis of IFSI III is. However, these results were not significant. The duration of CI did 
not correlate significantly with the clinical picture of the skin according to the IFSI classification. The 
mean severity of CI (VAS) showed a significant correlation only with IFSI III. The first representative 
study on CI in HD patients demonstrates that dermatological diseases and findings are frequent in 
HD patients and that CI is still a major burden in this patient population.    
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Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis
M Murakami,1 T Kaneko,2 T Nakatsuji,3 K Kameda,4 Y Hanakawa,1 M Tohyama,1 A Ishida-
Yamamoto2 and K Sayama1 1 Dermatology, Ehime University Graduate School of Medicine, 
Shitsukawa, Japan, 2 Dermatology, Asahikawa Medical University, Asahikawa, Japan, 3 
Medicine / Dermatology, University of California, San Diego, San Diego, CA and 4 Integrated 
Center for Science, Ehime University Graduate School of Medicine, Toon, Japan
“Pustulosis palmaris et plantaris”, or palmoplantar pustulosis (PPP), is a chronic pustular dermatitis 
characterized by intraepidermal palmoplantar pustules. Although early stage vesicles (preceding 
the pustular phase) formed in the acrosyringium contain the antimicrobial peptides cathelicidin 
(hCAP-18/LL-37) and dermcidin, the details of hCAP-18/LL-37 expression in such vesicles remain 
unclear. The principal aim of this study was to clarify the manner of hCAP-18/LL-37 expression 
in PPP vesicles and to determine whether this material contributed to subsequent inflammation of 
lesional skin. PPP vesicle fluid (PPP-VF) induced the expression of mRNAs encoding IL-17C, IL-8, 
IL-1α, and IL-1β in living skin equivalents, but the level of only IL-8 mRNA decreased significantly 
upon stimulation of depleted PPP-VF. Semi-quantitative dot-blot analysis revealed higher concen-
trations of hCAP-18/LL-37 in PPP-VF compared to healthy sweat. The average concentration of 
hCAP-18/LL-37 in PPP-VF was adequate to upregulate expression of IL-17C, IL-8, IL-1α, and IL-1β 
at both the mRNA and protein levels. Recombinant hCAP-18 was incubated with PPP-VF depleted of 
hCAP-18/LL-37, and the processing to the active form (LL-37) was detected in it. Proteinase 3, which 
converts hCAP-18 to LL-37, was present in PPP-VF. Histopathological and immunohistochemical 
examination revealed that early stage vesicles contained many CD68-positive mononuclear cells 
but no polymorphonuclear cells. In conclusion, PPP-VF contains the proteinase required for LL-37 
processing and also may directly upregulate IL-8 in lesional keratinocytes by LL-37 induction, in 
turn contributing to the subsequent inflammation of PPP lesional skin.    
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Omalizumab normalizes levels of high affinity immunoglobulin E receptor-positive skin cells 
in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-con-
trolled study
M Metz,6 P Staubach,1 A Bauer,2 R Brehler,3 J Gericke,6 J Ashton-Chess,4 P Jarvis,4 J Canvin,5 
VJ Erpenbeck4 and M Maurer6 1 Hautklinik, Universitätsmedizin der Johannes Gutenberg-
Universität Mainz, Mainz, Germany, 2 Hautklinik, Universitätsklinikum Carl Gustav Carus, 
Dresden, Germany, 3 Klinik für Hautkrankheiten, Universitätsklinikum Münster, Münster, 
Germany, 4 Novartis, Basel, Switzerland, 5 Novartis, Horsham, United Kingdom and 6 
Allergie-Centrum-Charité, Klinik für Dermatologie, Venerologie und Allergologie, Berlin, 
Germany
Many patients with chronic spontaneous urticaria (CSU) who are symptomatic despite antihistamines 
respond to the humanized monoclonal anti-IgE antibody omalizumab (Xolair), but the mechanism 
of action (MoA) is not completely understood. A randomized, double-blind, placebo-controlled 
study in CSU patients (18-75 years) was performed to explore the MoA of omalizumab in CSU, 
specifically effects on high-affinity IgE receptor-positive (FcεRI+) and IgE-positive (IgE+) skin cells, 
and also assessed efficacy (UAS7). Patients received 300 mg omalizumab (n=20) or placebo (n=10) 
s.c. q4weeks for 12 weeks. Lesional and non-lesional skin was biopsied at Days 1, 8, 29, 85 and 
140. Biopsies from 10 untreated healthy volunteers (HVs) provided reference data. Baseline levels 
of FcεRI+ and IgE+ skin cells were higher in CSU patients than HVs. At Day 85, UAS7 decreased 
significantly more with omalizumab than placebo (mean ± SD: 23.1 ± 12.9 vs. 8.11 ± 4.5, p=0.0027), 
consistent with previous studies. Levels of FcεRI+ cells declined in omalizumab patients in lesional 
(mean -5.4 p = 0.046 vs baseline) and non-lesional skin (mean -5.4, p = 0.026). Decreases were seen 
by Day 8 and continued to Day 85. Levels of IgE+ skin cells also declined in omalizumab patients 
(mean lesional -5.7, p = 0.135, non-lesional -4.9, p = 0.058). Levels of FcεRI+ and IgE+ cells in omal-
izumab patients at D85 had declined to levels seen in HVs. No meaningful changes were observed 
in the placebo group. Omalizumab was effective in the treatment of CSU, and appears to decrease 
levels of FcεRI+ and IgE+ cells in CSU patients to levels similar to those in healthy individuals.   
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3-year safety data of propranolol therapy for severe infantile hemangioma: report of the 
French experience from the Compassionate Use Program database 
S Prey,1 K Ezzedine,1 JJ Voisard,2 C Labreze1 and A Taieb1 1 Inserm U1035, Bordeaux, France 
and 2 Laboratoire Pierre Fabre Dermatologie, Lavaur, France
Since 2008, propranolol has become the first line treatment of severe infantile hemangioma (IH), 
although few data are available on the safety of betablockers in the pediatric-specific population. 
Our study analyzed the prospective vigilance cohort of the French compassionate use program 
(CUP) for the use of a new paediatric formulation of oral propranolol. Consecutive patients with 
proliferating IH requiring systemic therapy were included in the CUP database from 2010 to 2013. 
Demographic data, characteristics of IH were collected at inclusion. Safety data were collected 
during treatment intake and until 2 years after treatment initiation. 922 children were included in 
the CUP, 74.9% were girls (sex ratio 3:1) with a median age of 114 days at inclusion. Forty percent 
of target IH were ulcerated, 72.4% led to functional impairment and 16.2% were life-threatening. 
The median dosage of propranolol was 2 mg/kg/day and median exposure duration was 6.5 months. 
Propranolol was discontinued following good efficacy in 83.7% of patients. We found 104 adverse 
events (AE) in 81 patients (8.8%), including 24 patients (2.6%) with serious adverse events. Most 
frequent AE were respiratory (38.3% of all patients with AE) with mainly bronchiolitis and bronchitis. 
Other AE included sleep disorders (24.7%), vascular AE (11.1%) with hypotension and acrocyanosis, 
and digestive AE (11.1%) with mainly diarrhea. Serious AE were respiratory (41.7% of all SAE), 
metabolic (hypoglycemia: 16.7%), cardiovascular (bradycardia: 12.5% and peripheral vascular 
AE: 8.3%). Most AE were transient and allowed maintenance or reintroduction of propranolol. In 
this first large prospective cohort of children treated with propranolol, the treatment was overall 
well tolerated. However, prescribers and caretakers must consider carefully the potential severe 
risk of bronchoreactivity during bronchial infection, and the risk of hypoglycemia in case of low 
food intake or fasting.    
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A comparison of elastic fibres in atrophic and hypertrophic facial photoageing
J Ayer,1 AK Langton,1 J Wilkinson,2 RE Watson,1 TW Griffiths1 and CE Griffiths1 1 
Dermatology Centre, The University of Manchester, Mancester, United Kingdom and 2 
Population Health, Salford Royal Teaching Hospital, Salford, United Kingdom
Photoageing of facial skin combines chronological ageing and the effects of cumulative exposure to 
ultraviolet (UV) radiation. Clinically, two main phenotypes exist: atrophic smooth skin (AP), prone 
to the development of non-melanoma skin cancers; and hypertrophic wrinkled skin (HP) that is less 
susceptible to skin cancer. The mechanisms that underpin these two disparate phenotypes are poorly 
understood. The aim of the current study was to compare and contrast the histological differences 
between phenotypic groups. Subjects with either the AP or HP facial photoageing phenotype who 
were non-smokers with no history of inflammatory skin disease were selected (n=8 each group; AP, 
79.1y±3.5; HP, 79.6y±2.6). All subjects had 4mm skin biopsies taken from UV-exposed facial skin 
(upper zygomatic arch). The percentage of elastin deposition (Weigert’s resorcin fuchsin), calcu-
lated between the dermal-epidermal junction (DEJ) to a maximal dermal depth of 400μm by image 
analysis, was significantly increased in HP (mean ± SE; 34.1% ± 7.7) as compared to AP (16.1% 
± 6.6; p=0.038). Fibrillin-rich microfibrils were identified by peroxide immunohistochemistry, the 
percentage of deposition was calculated between the DEJ to a maximal dermal depth of 50μm. 
AP (21.8% ± 1.1) contained significantly more fibrillin-rich microfibrils than HP (10.4% ± 1.8; p< 
0.001). There was no significant difference in DEJ convolution as rête ridge effacement associated 
with chronic photoageing occurred in both groups. In summary, AP photoaged facial skin had less 
solar elastosis but more fibrillin-rich microfibrils than the HP phenotype. It appears that AP and HP 
photoageing are distinct histological entities and further investigation is warranted to determine 
underlying mechanisms which in turn may provide insight into the risk of skin cancer development.   
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Adalimumab Improves Treatment Satisfaction with Medication (TS-M) in Patients with Mod-
erate to Severe Hidradenitis Suppurativa (HS) in a 12-week Randomised Controlled Trial 
(PIONEER I)
GB Jemec,1 M Sundaram,2 B Pinsky,2 Y Gu,2 D Williams2 and Y Bao2 1 University of 
Copenhagen, Roskilde, Denmark and 2 AbbVie Inc., North Chicago, IL
HS is an inflammatory skin disease characterized by recurrent, painful lesions that may lead to 
physical debilitation and psychological strain. Recent data indicate that TNF-alpha blockage is 
of benefit to patients (pts) with HS. Patient satisfaction is an important outcome parameter in the 
assessment of treatment, and was studied in a phase 3 clinical trial to evaluate the safety and effi-
cacy of adalimumab (ADA) vs placebo (PBO) in pts with moderate to severe HS. This multicenter 
study included a 12-week, double-blind, PBO-controlled period (Period A) followed by 24 weeks 
of double-blind treatment. For Period A, pts were randomized 1:1 to ADA (160 mg at week 0; 80 
mg at week 2; 40 mg weekly from week 4) or matching PBO. At baseline, pts had a diagnosis of 
HS for ≥1 year, a total abscess and inflammatory nodule count ≥3, HS lesions in ≥2 body areas, 
Hurley Stage II or III, and were anti-TNF–naïve. TS-M was measured using the Treatment Satisfaction 
Questionnaire for Medication (TSQM). The TSQM has 14 items across 4 domains: effectiveness, 
side effects (SE), convenience, and global satisfaction (GS). Each domain is rated on a 100-point 
scale with higher scores indicating greater TS-M. Pts receiving ADA reported having greater GS 
with treatment at week 12 compared with PBO pts (56.5 vs 46.9; p=0.004). Further, pts rated ADA 
better on effectiveness than PBO (51.3 vs 39.7; p<0.001). No difference in SE was experienced 
by pts receiving active treatment vs PBO (91.9 vs 93.3; p=0.55). In addition to the higher score at 
week 12, ADA pts had a larger improvement from baseline to week 12 in both effectiveness (19.8 
vs 8.5; p=0.001) and GS (17.0 vs 8.4; p=0.009). In conclusion, pts with moderate to severe HS 
receiving ADA were more satisfied with their treatment than pts receiving PBO whilst both groups 
had a similar perception of SE.    
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Advances in the preclinical prediction of skin drug levels and systemic exposure in patients 
after topical treatment 
B Liehl, J Meingassner, H Fahrngruber, V Gruber, P Stuchlik, R Heiling, H Aschauer, A Stuetz 
and E Kriehuber Dermatology, NIBR, Vienna, Austria
Reliable drug level determination in skin after topical treatment in a clinical setting is challenging 
due to several reasons, e.g. the high risk of contamination with non-absorbed drug present on the 
treated skin surface. Given the similarity between human and pig skin, we developed a pre-clinical, 
4-tiered approach for the prediction of drug levels in man after topical application. This system 
included evaluation of 1) penetration into and permeation through normal human and pig skin in 
vitro; 2) in vivo kinetics of permeation through pig skin into the systemic circulation; 3) in vivo 
kinetics of penetration into the dermis of pigs after single application and 4) penetration into and 
permeation through inflamed pig skin in vitro and in vivo. These parameters allow the compilation of 
a pharmacokinetic profile for a given substance which is considered to be predictive for the human 
situation. In addition, the preclinical prediction system has been further refined by establishing a 
method to determine depth of drug penetration via serial sectioning of punch biopsy samples taken 
from heat-deepidermized and frozen skin treated with the compound of interest. Sections were 
analysed analytically for their drug content with liquid chromatography mass spectrometry. As 
expected we found that the decline of drug concentration was a function of tissue depth. A model 
compound gave favorable drug levels only within the upper 200μm dermal layer, whereas in the 
following deeper layers (200-400μm, 400-600μm, 600-800μm) levels were substantially decreased 
to 16%, 2% and 1% of the initial value, respectively. The described method allows the translational 
testing whether a pharmacologically active compound will reach target dermal layers of interest in 
sufficient amounts, which is a prerequisite for successful therapeutic intervention.    
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Alcohol intake, as measured by phosphatidylethanol in blood and the Lifetime Drinking 
History questionnaire, is correlated with extent of psoriasis. 
L Zou,2 S Lonne-Rahm,1 A Helander,3 K Stokkeland,5 J Franck4 and K Nordlind1 1 Department 
of Medicine, Dermatology and Venereology Unit, Karolinska Institutet, Karolinska University 
Hospital, Solna, Stockholm, Sweden, 2 Dermatology and Venereology Clinic, Sodersjukhuset, 
Stockholm, Sweden, 3 Department of Laboratory Medicine, Karolinska Institutet, and 
Karolinska University Laboratory Huddinge, Stockholm, Sweden, 4 Department of Clinical 
Neuroscience, Division of Psychiatry, Karolinska Institutet, Stockholm, Sweden and 5 
Department of Medicine, Visby Hospital, Visby, Sweden
The purpose of this study was to investigate alcohol use in individuals with psoriasis and correlate 
this intake with the extent of the disease and degree of pruritus. A cross-sectional study was per-
formed. Twenty-nine patients (15 females and 14 males) with stable chronic plaque psoriasis of 
moderate severity, on topical treatment only, were recruited. The Psoriasis Area and Severity Index 
(PASI) and the degree of pruritus (Visual Analogue Scale) were compared with measures of drinking 
habits as determined by the Lifetime Drinking History (LDH), the Alcohol Use Disorders Identifica-
tion Test (AUDIT), and whole blood phosphatidylethanol (PEth), an alcohol specific biomarker. The 
self-reported use of alcohol according to the AUDIT and LDH questionnaire, positively correlated 
with the PEth concentration in blood. The severity of disease, as measured by the PASI, positively 
correlated with alcohol use during the past year and the past week as assessed by LDH, and also with 
the blood levels of PEth. When this group of individuals was separated between sexes, significant 
correlations between disease severity and the LDH and PEth were noted for females, but not for 
males. In individuals with psoriasis, the level of alcohol consumption is correlated with the extent 
of disease. No correlation with pruritus was found.    
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Analysis of the cutaneous kappa opioid receptor expression in dermatoses associated with 
pruritus
T Lotts, I Born and S Ständer Department of Dermatology and Competence Center Chronic 
Pruritus, University of Münster, Münster, Germany
Translational research in chronic pruritus aims to identify potential candidates for a target-specific 
therapy in pruritic dermatoses which is urgently needed. A potential target candidate is the periph-
erally expressed kappa opioid receptor (OPRK1), which is expressed in various cell types in the skin, 
such as keratinocytes, macrophages and sensory nerve fibers. The aim of the present study was to 
determine the cutaneous expression level of OPRK1 in lesional, pruritic skin by means of immuno-
fluorescence and western blot. In total, > 330 biopsies of different dermatoses (e.g., atopic dermatitis 
(AD), psoriasis (PSO), prurigo nodularis (PN), lichen planus, urticaria, mastocytosis, cutaneous T-cell 
lymphoma (CTCL)) have been analyzed and compared to healthy controls (HC). OPRK1 was found 
in all patients mainly in the epidermal basal keratinocytes and, suprabasally in AD, PSO, PN and 
lichen planus whereas dermal inflammatory cells expressed OPRK1 only weakly. The signal in 
western blot analysis was significantly higher in AD (p<0.05) and CTCL (p<0.05) compared to HC. 
The levels in PSO were slightly down-regulated, with no difference seen between other dermatoses 
and HC skin. Further analysis with separated epidermis and dermis showed a main signal in the 
epidermis. Our results indicate that peripheral OPRK1 is an interesting target especially in AD and 
CTCL. Current studies investigate the role of epidermal OPRK1 using novel peripheral agonists.   
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Anti-TNFα agents are effective therapies in patients suffering from Behçet’s Disease 
C Castellucci, J Griss, T Kinaciyan, G Stingl and A Jalili Department of Dermatology, Division 
of Immunology, Allergy and Infectious Diseases (DIAID), Medical University of Vienna, 
Vienna, Austria
Behçet’s Disease (BD) is a systemic recurrent vasculitis, which is often resistant to conventional 
therapies. Recently, anti-TNFα agents have shown promising results for the treatment of patients 
suffering from BD. In this study anti-TNFα agents infliximab, adalimumab and etanercept were com-
pared in regards to efficacy and safety in BD patients treated in our center. Data of 16 BD patients, 
who were treated with the anti-TNFα agents infliximab (n=7), adalimumab (n=8) and etanercept 
(n=1) from 2002 to 2014, was reviewed retrospectively through medical records and information 
on improvement or worsening of symptoms as well as adverse events was collected. Altogether, an 
improvement of symptoms occurred in 12 patients, showing no statistically significant differences 
(p=1.000) between infliximab (n=5) or adalimumab (n=6) groups. Noted adverse events were a case 
of demyelinating disease, a miliary tuberculosis and an angioedema in the infliximab group as well 
as two cases of recurrent upper respiratory tract infections and one case of erythema multiforme in 
the adalimumab group. The incidence of side effects in both groups was also statistically insignif-
icant (p=1.000). During the course of therapy four patients switched anti-TNFα agents (n=2 from 
infliximab to adalimumab and n=2 from adalimumab to infliximab) due to lack of efficacy (n=1), 
patient’s request (n=2) or adverse event (n=1). All patients who switched agents showed a positive 
response to the other anti-TNFα agent. The patient treated with etanercept did not experience any 
adverse events and experienced a successful clinical response. Despite the low number of patients 
in this study, we can conclude that both infliximab and adalimumab seem to be equally effective 
in management of BD, presenting no difference in the occurrence of adverse events. Additionally, 
switching anti-TNFα agents was safe and led to a remission of symptoms in BD patients.    
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Artificial antigen-presenting cells trigger highly cytotoxic CD8+ T lymphocytes with restricted 
repertoire diversity 
J Chatillon,1 M Hamieh,2 F Bayeux,1 E Fauquembergue,2 A Drouet,2 A Modeste,3 P Joly,3 
S Calbo,1 J Latouche2 and P Musette1 1 U905, INSERM, Rouen, France, 2 U1079, INSERM, 
Rouen, France and 3 Dermatology, Rouen University Hospital, Rouen, France
We have studied the T Cell Receptor (TCR) repertoire of anti-melanoma CTLs generated in an adop-
tive immunotherapy strategies based on the use of artificial antigen-presenting cells (AAPC). Artificial 
CTL activating systems have been developed based on the use of artificial antigen-presenting cells 
(AAPCs). These AAPCs have been transduced to express molecules involved in the immunological 
synapse restricted to the HLA-A*0201 molecule, and essential to activate CTLs against MART-1 (M1), 
an auto-antigen overexpressed in melanoma. We have studied T Cell Receptor (TCR) repertoire of 
AAPC-activated M1-specific CTLs from healthy donors and melanoma patients, through Vb subfam-
ily and CDR3 analyses. We observed that the most expanded Vβ subfamilies displayed oligoclonal 
distributions, with sequences shared between healthy donors and patients, and a dominant clone 
representing more than 50% of total CTLs. After T cell sorting based on Vβ expression, CTLs from 
the dominant Vβ subfamily displayed higher functional avidity, higher perforine and granzyme B 
production, and effector memory phenotype (CD45RA+CD62L-CCR7-). Altogether, our data reveal 
that, in the AAPC-based CTL stimulation, the dominant responding Vβ subfamily has an oligoclonal 
distribution, with the higher cytotoxic capacities and an effector memory phenotype. Therefore, 
AAPCs could be interesting to expand perfectly characterized highly cytotoxic CD8+ population 
in a reproducible manner.    
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Baseline characteristics of patients with psoriasis enrolled in the British Association of Der-
matologists’ Biologic Interventions Register. 
I Iskandar,1 R Warren,2 Z Yiu,2 J Barker,3 D Burden,4 A Ormerod,5 N Reynolds,6 C Smith,3 
C Griffiths2 and D Ashcroft1 1 Manchester Pharmacy School, University of Manchester, 
Manchester, United Kingdom, 2 Dermatology Centre, University of Manchester, Manchester, 
United Kingdom, 3 St. John’s Institute of Dermatology, London, United Kingdom, 4 
Dermatology Department, Western Infirmary, Glasgow, United Kingdom, 5 Applied 
Medicine, University of Aberdeen, Aberdeen, United Kingdom and 6 Dermatological 
Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
The British Association of Dermatologists’ Biologic Interventions Register (BADBIR) is a large pro-
spective observational cohort designed to assess the long-term safety of biologic and conventional 
systemic therapies for severe psoriasis. The aim was to analyse baseline demographics, disease 
severity, current & previous systemic therapies, and co-morbidities. Baseline data were collected 
from 146 Dermatology departments in the UK & Ireland. From Sept 2007 - Oct 2013, 7110 patients 
were registered with 4283 (60%) receiving biologics of whom 51% were on adalimumab, 27% 
etanercept, 17% ustekinumab & 5% infliximab. In the comparator cohort 44% were on methotrex-
ate, 23% ciclosporin,18% acitretin & 8% fumaric acid esters. 4192 (59%) were male. Mean (±SD) 
age & disease duration of patients on biologics were 46±13 years & 23±13 years respectively, while 
patients on conventional therapies had a lower age (44±14 years) & shorter disease duration (19±13 
years). Mean BMI for patients on biologics (31±7 Kg/m2) was higher than those on conventional 
systemic therapies (30±7 Kg/m2). Mean baseline PASI and DLQI scores were higher in patients on 
biologics compared to those on conventional systemics (17±8 vs 16±8 & 18±8 vs 15±7, respectively). 
68% of all patients had co-morbidities & 41% had more than one. The most frequent co-morbidities 
were hypertension (26%), depression (22%) & psoriatic arthritis (16%). BADBIR is an invaluable 
resource to study the safety & effectiveness of biologic and conventional systemic therapies in routine 
clinical practice for severe psoriasis. Understanding differences in baseline characteristics between 
cohorts will be crucial in undertaking future pharmacovigilance studies.    
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Changing phenotype of coeliac disease: from classical disease to dermatitis herpetiformis
T Salmi,3 K Hervonen,3 K Kurppa,2 P Collin,1 K Kaukinen3 and T Reunala3 1 Gastroenterology, 
Tampere University Hospital, Finland, Finland, 2 Tampere Center for Child Health Research, 
Tampere, Finland and 3 Tampere University, Tampere, Finland
Dermatitis herpetiformis (DH) is a cutaneous form of coeliac disease affecting approximately 17% 
of coeliac disease patients. Lifelong gluten-free diet (GFD) is the treatment of choice for DH equally 
as for coeliac disease. The aim of this study was to determine how often coeliac disease precedes 
the development of DH, and what is the impact of GFD in this. Our prospectively collected DH 
series from 1970 comprises 514 patients. In this study we analyzed all those DH patients who at 
least two years earlier had been diagnosed with coeliac disease. DH diagnosis was confirmed by 
showing immunoglobulin A deposits in dermis by direct immunofluorescence. Serological and small 
bowel mucosal findings were analyzed, and the strictness of GFD treatment before and after the 
diagnosis of DH was evaluated. Twenty (4%) DH patients had a prior diagnosis of coeliac disease. 
The median time interval between the detection of coeliac disease and DH was 9.5 (range 2-34) 
years. Before DH appeared four patients had been on a normal gluten-containing diet, 10 (50%) had 
dietary lapses on a GFD and only six were on a strict GFD. Coeliac autoantibodies were positive 
in 37% of the patients, and five out of seven undergoing small bowel biopsy evinced partial villous 
atrophy in small bowel specimens. Following DH diagnosis the rash was controlled after a median 
of 6 (range 1-84) months on a strict GFD. Patients with coeliac disease may develop DH by time. 
This is most often an indicator of poor adherence to GFD. After diagnosed by dermatologist, the 
possible defects in GFD can be corrected and the patients will respond to the dietary treatment as 
ordinary DH patients.    
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CK7, TTF-1, p53 and CM2B4: A possible histologic indicator for divergent differentiation of 
Merkel cell carcinoma
K Nagase, S Koba, N Misago and Y Narisawa Dermatology/Internal Medicine, Saga 
University, Saga, Japan
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high mortality 
rate. An international consensus staging system was adopted in 2010, but there remains a clinical 
need to identify biomarkers to refine prognosis. The majority of MCCs develops de novo and is 
histologically pure. A subset of MCCs (collision MCCs), however, is found in divergent differenti-
ation and intimate association with dysplastic changes of overlying and adjacent epithelium. The 
biological behavior of collision MCCs are still uncertain. We have herein assessed the correlation 
of immunohistological detection of aberrant differentiation and association with surrounding epithe-
lium in MCCs to determine the relative value of various markers. In our study, 14 MCC specimens 
were examined histologically and immunohistochemically. Hematoxylin-eosin staining showed 
that, of 14 MCC cases, 6 were pure MCCs and 8 showed divergent differentiation (collision MCCs). 
Some cases showed dysplastic changes in the overlying and adjacent epithelia. For clarifying the 
association between differentiation and expression of variable markers of MCCs, neuroendocrine, 
epithelial, mesenchymal, stem cell, and follicular differentiation markers were used to evaluate the 
immunohistochemical phenotypes. In all cases with collision MCCs, neuroendocrine component 
of MCC expressed CK7, TTF-1 and p53 with a high frequency, but no CM2B4. On the other hand, 
none of pure MCCs tested expressed CK-7, TTF-1 and p53.Our results suggest that immunohisto-
logical detection of CK7, TTF-1, p53 and CM2B4 is of value in the histologic indicator for divergent 
differentiation of MCC (collision MCCs) and facilitates a retrospective and prospective study of 
prognostic implication of divergent differentiation of MCC. However, larger series of cases will be 
required to determine if aberrant differentiation and dysplastic changes of surrounding epithelium 
represents another negative prognostic factor.    
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Clinical effect of a moisturizing cream containing an oligomer ester, diethylene glycol/dilin-
oleic acid copolymer, on senile pruritic xerosis
R Izumi,1 O Negi,2 T Suzuki,1 S Matsukuma1 and K Takamori2 1 FANCL research institute, 
Yokohama, Japan and 2 Dermatology, Juntendo University Urayasu Hospital, Urayasu, Japan
Pruritus is the most common symptom of skin disease in the elderly. Patients with senile xerosis often 
experience severe itching, which could influence the quality of life. A previous study showed that the 
oligomer ester, diethylene glycol/dilinoleic acid copolymer (D/DC), had a significant moisturizing 
effect on atopic dermatitis. In the present study, we aimed to evaluate the anti-itching effect of a 
topical cream containing D/DC in patients with senile pruritic xerosis. We performed a single-blind 
study of 50 subjects aged 50 to 75 years, who were randomly divided into the 10%D/DC cream, 
20%D/DC cream, white petrolatum, and no-treatment groups. The subjects were instructed to 
apply D/DC creams and white petrolatum to the lower legs for 4weeks. The clinical scores (skin 
dryness and scratch marks) and electrochemical skin conductance were evaluated before and 
after treatment, and the visual analogue scale (VAS) score for skin itching was assessed once a 
week. Compared with the no-treatment group, the white petrolatum group showed improvement 
in only the skin dryness scores, whereas the 10%D/DC and 20%D/DC groups showed significant 
improvements in the skin dryness and scratch marks scores, as well as increased skin conductance. 
Furthermore, the 20%D/DC group showed greater improvements in the skin dryness scores and 
skin conductance than the white petrolatum group. The VAS score of the D/DC groups and white 
petrolatum group significantly decreased compared to the no-treatment group. In particular, after 
1 week of treatment, the VAS score was significantly lower in the 20% D/DC group than in the 
other groups. In conclusion, the moisturizing cream containing D/DC significantly improved skin 
dryness and pruritus in a dose-dependent manner. Therefore, the application of this cream may be 
effective for the management of dry and itchy skin in senile xerosis.    
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Deciphering the aquagenic pruritus in patients with myeloproliferative neoplasms : not exclu-
sive of Polycythemia Vera. 
C Le Gall-Ianotto,2 B Emilie,3 M Gouillou,4 E Nowak,4 K Lacut,4 A Tempescul,1 V Ugo,5 
L Misery3 and J Ianotto1 1 Department of Hematology, CHRU of Brest, Brest, France, 2 
laboratory of Neurosciences of Brest, Brest, France, 3 Department of Dermatology, CHRU of 
Brest, Brest, France, 4 CIC INSERM 0502, CHRU of Brest, Brest, France and 5 Laboratory of 
Hematology, CHRU of Brest, Brest, France
Pruritus is frequently reported in myeloproliferative neoplasms (MPN) as polycythemia vera (PV) 
or myelofibrosis (MF), rarely in essential thrombocythemia (ET). In PV, pruritus is aquagenic (AP) ie 
it is induced after contact with water. This intense prickling and stinging sensation anneals quality 
of life (QoL) of patients. What about of pruritus in MF and ET? We conducted a prospective study 
(questionnaire) on 70 MPN patients (44 PV, 14 ET, 12 MF, all JAK2V617F positive) who reported 
suffering from AP at the onset or later during the course of their MPN. The main objective was 
to describe circumstances of occurrence, duration and characteristics of pruritus, and influence 
of received cytoreductive treatments. Secondary objective was to determine whether there is a 
single symptom whatever the MPN or if there are several types of AP depending on MPN. Our 
results revealed that AP is described in ET and MF too. It occurred earlier prior to diagnosis in PV 
(p<0.05) and is more sensitive to any contact with water (p<0.05). A significant influence of water 
temperature was revealed in PV and MF but not in ET, and crisis are longer and more disabling 
with scratching till excoriation (p<0.05). In contrast, there is no statistical difference between MPNs 
concerning the inducer of AP, type of pruritus, affected body areas, intensity and the overall impact 
on QoL. At questionnaire time, 42/70 patients (8 ET, 6 MF, 28 PV) still suffered from AP despite a 
complete hematological response for 20 patients. Cytoreductive treatments were significantly more 
efficient to resolve AP in ET and MF. So, this study shows that AP is not an exclusive symptom of 
PV and describes some clinical differences between MPNs that could help to better understand AP 
physiopathology and find better therapies.    
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Efficacy of bath-PUVA therapy for all stage of mycosis fungoides -retrospective anlysis of 
62 cases 
E Nishida, Y Shintani, M Nakamura, S Yamazaki and A Morita Department of Geriatric and 
Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, 
Nagoya, Japan
Photochemotherapy with psoralen and UVA (PUVA) is widely used as an effective treatment for 
refractory skin diseases. Although PUVA has become less popular, as narrowband UVB has become 
more popular, bath water delivery of 8-methoxypsoralen and subsequent UVA-irradiation (bath-
PUVA) remains an effective alternative to systemic application and the gold standard of photother-
apy modalities. In our previous studies, bath-PUVA induced circulating regulatory T cells (Tregs), 
which also acquired the suppressive function, in patients with psoriasis. However, the underlying 
mechanism for mycosis fungoides (MF) remains unclear. To understand the mechanisms in MF, we 
analyzed lesional infiltrating cells before and after bath-PUVA therapy. Bath-PUVA decreased CCR4 
expressing malignant T cells with reduction of Tregs in MF lesions. The efficacy of bath- PUVA for 
early-stage of MF was well documented. In this study, we conducted a retrospective analysis of all 
the stages of MF patients treated with bath-PUVA at Dermatology clinic in Nagoya City University 
Hospital between November 2004 and 2013. Sixty-two patients with MF (8 stage IA, 30 stage IB, 
5 stage IIB, 17 stage IIIA, 1 IVA2) were analyzed. Of the 62 patients in the study, 47 (75.8%) had 
complete response (CR), 7 patients (11.3%) had partial response, and 8 patients (12.9%) had no 
response (NR). The almost patients with IA/IB and IIIA achieved CR. One of 5 IIB patients achieved 
CR and two was PR. Serum sIL-2R and LDH levels in patients after bath-PUVA were significantly 
decreased (P<0.001). Several factors related to disease progression were identified in our data. 
Patients in MF with tumor showed high odds ratio (13.0 [1.952-86.579], p =0.016). We report the 
largest study of bath-PUVA for all the stages of MF. Bath-PUVA is highly effective for the early stage 
and partially effective advanced stage. Depending the stage and progression, the photobiological 
mechanisms should be analyzed to maximize the efficacy of bath-PUVA.    
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Efficacy of D-delta-tocopheryl retinoate in the improvement of photodamaged skin 
DG Mercurio,1 LS Calixto,1 E Bagatin2 and PM Maia Campos1 1 School of Pharmaceutical 
Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto, Brazil and 2 Department 
of Dermatology, Federal University of São Paulo - UNIFESP, São Paulo, Brazil
Photoaging is characterized by wrinkles, mottled pigmentations, loss of skin tone, laxity, dryness 
and roughness of the skin. All-trans-retinoic acid is a potent anti-aging ingredient, however, due 
to its irritancy and mutagenicity, several less aggressive retinoids derivatives have been proposed. 
Among these, D-delta-tocopheryl retinoate (TR) is presented as a differentiated active ingredient for 
improving photodamaged skin conditions. Thus, the aim of this study was to evaluate the clinical 
efficacy of 0.1% of TR in cosmetic formulations using biophysical and skin imaging techniques and 
clinical evaluation. For this purpose, 40 healthy female volunteers aged between 40-65 years-old 
applied daily a formulation containing, or not, (vehicle) 0.1% of TR on the face for 12 weeks. Their 
effects were evaluated before, and after 4, 8 and 12 weeks using biophysical and skin imaging 
techniques. At the end of the study, self assessment and clinical score evaluation were performed. 
After 4 weeks of application of the formulation with TR, a significant increase of the stratum corneum 
water content, and reduction of the skin roughness were observed. These results sustained for the 12 
weeks of the study. An increase of skin elasticity and a reduction in skin transepidermal water loss 
were observed after 12 weeks of the study. It was not observed differences in dermis echogenicity. 
In the efficacy perception study, the volunteers perceived an improvement of skin hydration and 
smoothness and a reduction of the wrinkles and skin spots. Moreover, it was not described irrita-
tion and/or erythema caused by the product application. The clinical scores showed a reduction 
of uneven pigmentation and roughness, and improvement of skin tone. In conclusion, this study 
evidenced the potential of TR to be applied in photodamaged skin, which presented effects in skin 
hydration, elasticity, microrelief, barrier function, and skin pigmentation.    
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Efficiency of ustekinumab in the treatment
M Gordon dermatology, Clinical hospital, poznan, Poland
Biological drugs are becoming a standard treatment of psoriasis in Western countries. Unfortunately, 
it is very expensive method and therefore unattainable for all patients. That is the reason why 
resources allocated for this method of the treatment should be disposed properly. The administration 
of biologics to the patients who have already applied them in the past is associated with prolonged 
waiting for the results and often with temporary impairment of the general condition of the patient. 
We decided to investigate development of the response to the treatment with ustekinumab in 
patients with psoriasis who were previously treated with biological agents. The study included 
39 patients of the Regional Hospital in Poznan with psoriasis, including 6 women and 33 men 
age 19-69 years (mean: 41 years). 8 patients were diagnosed with psoriatic arthritis, and 31 with 
psoriasis vulgaris. Patients were coming for the check-ups and administration of the next dose of 
medication in the scheme 0-4-16-28-40-52 weeks. During these visits PASI, BSA and DLQI were 
determined, as well as information about adverse drug reactions. Patients got complete physical 
exam and a panel of laboratory tests. Decrease in PASI score was significantly greater in patients 
with psoriasis arthritis than in patients with psoriasis vulgaris. Ustekinumab can be used even after 
prior use of other biologics, having in mind that effects of the treatment will be delayed. The same 
applies to the patients previously treated with methotrexate. The effectiveness of ustekinumab 
treatment is independent of gender. The most visible results of the treatment appear after one to 
four months of the first taken dose.    
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Elafin is an indicator of poor prognosis in cutaneous graft-versus-host disease 
M Brüggen,1 P Petzelbauer,2 H Greinix,3 E Contassot,4 D Jankovic,4 L French,4 R Knobler,5 
G Stingl1 and G Stary1 1 Dpt of Dermatology, DIAID, Medical University of Vienna, Vienna, 
Austria, 2 Dpt of Dermatology, SERD, Medical University of Vienna, Vienna, Austria, 3 Dpt 
of internal Medicine 1, BMT Unit, Medical University of Vienna, Vienna, Austria, 4 Dpt of 
Dermatology, University Hospital Zurich, Zurich, Switzerland and 5 Dpt of Dermatology, Div 
of General Dermatology, Medical University of Vienna, Vienna, Austria
Graft-versus-host disease can occur in an acute (aGVHD) and a chronic (cGVHD) form with skin 
being the most commonly affected organ in both of them. Recent studies have identified the keratino-
cyte-derived elastase inhibitor elafin as an aGVHD biomarker in the peripheral blood. In this study, 
we addressed the question whether elafin expression in the skin is a diagnostic/prognostic marker of 
GVHD and could help to distinguish aGVHD from drug hypersensitivity rashes (DHR). Therefore, 
we collected skin biopsies from two independent aGVHD cohorts (n=22 and n=10), 15 cGVHD 
and 10 DHR patients. Cutaneous elafin expression was assessed (at the mRNA and protein level) 
as to its association with GVHD diagnosis/prognosis parameters. Our analyses revealed that elafin 
expression was heterogeneous in aGVHD and DHR rashes but not significantly different between the 
two. Although cutaneous elafin expression was overall higher in cGVHD as compared to aGVHD, 
both aGVHD and cGVHD patient cohorts could be subdivided in an elafin-high and -low group. 
Elevated elafin expression in aGVHD and cGVHD was associated with epidermal thickening and 
a trend towards a more prominent T cell infiltrate. Clinically, elafin-high aGVHD patients had a 
decreased 3-year overall survival and cGVHD patients more frequently presented a corticoste-
roid-resistant form of the disease. In conclusion, our study strongly suggests an association between 
cutaneous elafin expression and poor GVHD prognosis. Cutaneous elafin expression analysis is a 
possible prognostic tool that could facilitate the early identification of GVHD patients at high risk.   
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Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol 
plus betamethasone dipropionate in an innovative foam vehicle 
L Hollesen Basse,1 M Olesen,1 J Lacour2 and C Queille-Roussel2 1 LEO Pharma A/S, Ballerup, 
Denmark and 2 Centre de Pharmacologie Clinique Appliquée à la Dermatologie, Nice, 
France
A new aerosol foam formulation of the fixed combination calcipotriol 50μg/g (Cal) + betamethasone 
0.5mg/g (as dipropionate; BD) has been developed for treatment of psoriasis vulgaris. In vitro skin 
penetration (PermeGear® Franz system) and antipsoriatic effect (plaque test model in psoriatic 
patients) of the Cal/BD foam were compared with the fixed combination ointment (Daivobet®) as 
part of early exploratory investigations. In vitro, treatments were applied to full thickness pig ear 
skin (n=6), and diffusion of Cal/BD into skin and permeant was determined at 2, 6 and 21h. Higher 
levels of Cal/BD were found within skin samples at all timepoints with the foam vs ointment (Cal 
2h [% of applied 5mg/cm2 dose±SD]: 25±5% vs 12±5%, 6h: 32±9% vs 11±3%, 21h: 30±9% vs 
6.2±3.0%; BD 2h: 6.9±2.7% vs 4.8±2.2%, 6h: 7.3±4.5% vs 3.0±1.6%, 21h: 6.2±4.0% vs 2.6±1.2%), 
leading to significantly higher total content of Cal (P<0.001) and BD (P=0.002). Following Cal/BD 
foam application, Cal and BD levels within skin samples remained consistent across the 3 collection 
timepoints (P=0.34 and 0.46, respectively) indicating steady-state levels. Levels of Cal and BD that 
permeated through the skin were generally very low/below detection, with the exception of Cal 
at 21h (foam, 34±13%; ointment, 15±12%; P=0.026 between products). Clinically, the plaque 
test model showed a statistically significantly larger decrease in mean total clinical score (sum 
of erythema, scaling, infiltration scores) with Cal/BD foam (–6.0±[SD]1.3) vs ointment (–5.3±1.8; 
P=0.038) after 4 weeks of once-daily treatment (6 days/week, excluding Sundays) on target plaque 
test sites (5 cm2). To conclude, an in vitro model of skin penetration showed steady-state levels of 
Cal/BD that were significantly higher following Cal/BD foam application compared with the fixed 
combination ointment. Further to the in vitro findings, Cal/BD foam showed a significant improve-
ment in antipsoriatic effect vs ointment in psoriasis patients.    
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Evaluation of Infections With Secukinumab in a Pooled Analysis of 10 Clinical Studies of 
Moderate-to-Severe Plaque Psoriasis 
T Tsai,2 A Blauvelt,1 A Karpov,3 J Huang,4 S Cooper4 and T Fox3 1 Oregon Med Res Ctr, 
Portland, OR, 2 Dermatology, National Taiwan Univ., Taipei, Taiwan, 3 Novartis, Basel, 
Switzerland and 4 Novartis, East Hanover, NJ
Secukinumab, a fully human anti–IL-17A monoclonal antibody, has demonstrated rapid and robust 
efficacy with acceptable safety up to 52 weeks (wk) in moderate-to-severe plaque psoriasis. We 
evaluated the risk of infections with secukinumab in a pooled analysis of 10 phase 2 and 3 studies 
in a total of >3000 subjects treated with s.c. secukinumab 300 or 150 mg, etanercept (ETN) 50 
mg, or placebo (PBO). During induction period (to Wk 12), infection rates with secukinumab 
300 (25.8%; n=1173) and 150 mg (26.9%; n=1174) were numerically higher than PBO (20.6%; 
n=793), but comparable to ETN (25.7%; n=323). Serious infections were infrequent (0.1, 0.2, 0.3, 
and 0%, respectively). For entire treatment period (to Wk 52), exposure-adjusted incidence rates 
(IR per 100 subject-years) of infections with secukinumab 300 (91.1; n=1410) and 150 mg (85.3; 
n=1395) were comparable to PBO (101.9; n=793) and ETN (93.7; n=323), with the most frequent 
being nasopharyngitis (IR: 27.4, 26.9, 38.7, and 35.7, respectively). There was no imbalance in IR of 
serious infections with secukinumab 300 (1.36), 150 mg (1.05), PBO (0.99), and ETN (1.37); and no 
serious opportunistic infections, reactivation of latent TB or viral hepatitis infection, or disseminated 
or CNS herpes. The exposure-adjusted IR of Candida infections was higher with secukinumab 300 
(3.55) than 150 mg (1.85), PBO (1.00), and ETN (1.37). However, all events on secukinumab were 
mild/moderate and non-serious, were self-resolving or responded to standard anti-fungal therapy, 
and did not lead to drug discontinuation, while two subjects on ETN experienced severe events. 
Increased incidence of mild/moderate Candida infections with secukinumab was consistent with 
the implied role of IL-17A in host immunity against fungal mucocutaneous infections with certain 
Candida. In summary, the overall incidence of infections with secukinumab was similar between 
300 and 150 mg, and comparable to ETN and PBO over 52 wks.    
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Evaluation of Malignancy Risk With Secukinumab Treatment in a Pooled Analysis of  10 
Clinical Studies   of  Moderate-to-Severe Plaque Psoriasis  up to 52 Weeks 
P van de Kerkhof,1 B Strober,2 A Karpov,3 J Huang,4 S Cooper4 and T Fox3 1 Radboud Univ, 
Nijmegen, Netherlands, 2 Univ. of Connecticut Health Center, Farmington, CT, 3 Novartis, 
Basel, Switzerland and 4 Novartis, East Hanover, NJ
Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has demonstrated rapid, 
robust, and durable efficacy with acceptable safety up to 52 weeks in moderate-to-severe plaque 
psoriasis. Patients with psoriasis might be at an increased risk of malignancy due to psoriasis and 
the use of immunomodulating therapies. We evaluated the potential effect of secukinumab on the 
risk of malignancy in a pooled analysis of 10 phase 2 and phase 3 studies in >3000 subjects treated 
with subcutaneous secukinumab 300 mg (n=1410) or 150 mg (n=1395), etanercept 50 mg (ETN; 
n=323), or placebo (PBO; n=793). Given that PBO data were mostly from the first 12 weeks, the 
exposure-adjusted incidence rate (IR per 100 subject-years) was used to allow for comparison across 
treatments over the entire treatment period (up to Week 52). IR of malignant or unspecified tumors 
was comparable among secukinumab 300 mg (0.77), 150 mg (0.97), and ETN (0.68), but numerically 
lower than PBO (1.49); the majority of tumors were non-melanoma skin cancers (NMSC). There 
were no reports of lymphoma in any treatment group. For malignant or unspecified skin tumors, 
IR was also lower with secukinumab 300 mg (0.60), 150 mg (0.70), and ETN (0.34), compared to 
PBO (1.49), with the majority being NMSC (0.43, 0.61, and 0, respectively, for secukinumab 300 
mg, 150 mg, and ETN; 1.49 for PBO). When NMSC were excluded, IR of malignant or unspecified 
tumors was numerically higher with ETN (0.68) than secukinumab 300 mg (0.34) and 150 mg (0.35). 
In summary, the incidence of malignancy with secukinumab was similar between the 300 mg and 
150 mg doses, comparable to ETN, and lower than PBO. No cluster of specific malignancies in any 
treatment group was seen. Data collected to date in psoriasis showed no indication that secukinumab 
confers an increased risk for malignancy.    
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Generation and characterization of induced Pluripotent Stem (iPS) cells from Autosomal 
Recessive Congenital Ichthyosis patients – a new model system to study rare keratinization 
disorders
DL Cunha,2 KM Eckl,2 M Rauch,2 R Casper,1 M Gupta,4 P Nürnberg,1 M Schmuth,3 
J Zschocke,2 T Saric4 and HC Hennies2 1 Cologne Centre for Genomics, University of 
Cologne, Cologne, Germany, 2 Dept. Human Genetics, Ctr. Dermatogenetics, Medical 
University Innsbruck, Innsbruck, Austria, 3 Dept. of Dermatology, Medical University 
Innsbruck, Innsbruck, Austria and 4 Inst. for Neurophysiology, University of Cologne, 
Cologne, Germany
Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous skin disorder characterized 
by skin barrier dysfunction which presents severe scaling of the skin and erythema. Treatments for 
this disorder are only symptomatic, leading to the urgent need for suitable disease models. Hence, 
the aim of our project is to create iPSC-based in vitro skin models for ARCI to overcome the limited 
availability and lifespan of primary human keratinocytes in culture and provide a virtually endless 
source of these cells. We have been characterizing iPSC lines generated from two ARCI patients 
using the polycistronic STEMCCA virus system. Both cell lines presented typical features of iPSC 
including embryonic stem cell-like morphology and alkaline phosphatase activity. Immunocyto-
chemistry showed positive signals for pluripotency surface markers and embryonic nuclear factor 
NANOG. Results were supported by qRT-PCR, which showed strong expression of endogenous 
pluripotency genes, including NANOG. Genomic integrity was confirmed by karyotyping and 
microsatellite analysis, showing an identical profile of the iPSC lines compared to their parental 
fibroblasts. The iPSC are now being differentiated into ectodermal fate and further on to epidermal 
keratinocytes as initially shown by the expression of suitable markers such as KRT18 and KRT14. The 
generation of further iPSC lines from ARCI patients is in progress. Our approach promises straight 
forward cellular models for the functional study of genetic variants and for the assessment of novel 
pharmacological interventions leading to patient-specific therapies for ARCI.    
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Human papillomavirus (HPV), Merkel cell polyomavirus (MCV), HIV and non-melanoma 
skin cancer
SI Goolamali,1 T Shim,1 K Purdie,2 N Mladkova,2 N Francis,1 CA Harwood2 and C Bunker1 
1 Dermatology, Chelsea and Westminster Hospital, London, United Kingdom and 2 Blizard 
Institute, QMUL, London, United Kingdom
Both immunosuppression and viral infections may be associated with skin cancer. We have inves-
tigated the roles of HPV (human papillomavirus), MCV (merkel cell polyomavirus) and HIV in 
actinic keratoses (AK), squamous cell carcinoma (SCC)-in situ (CIS), penile pre-cancer (PCIS) and 
non-melanoma skin cancer (NMSC) - basal cell carcinoma (BCC), SCC & penile SCC. Amplifiable 
DNA was extracted from microdissected, formalin-fixed, paraffin-embedded tissue from 191 clini-
cal samples (43AK,25CIS,79BCC,34SCC,8PCIS,2Penile SCC); 98/191(51%) samples were HIV+ve. 
Highly sensitive broad spectrum HPV DNA detection assays were used to identify cutaneous and 
mucosal HPVs. PCR detection of MCV DNA used 2 sets of primers:- MCVPS1 (small tumour antigen) 
and MCPyV (large tumour antigen). 44/191(23%) samples were MCV+ve. 8/44(18%) positive for 
MCVPSI primer, 41/44(93%) positive for MCPyV primer and 5/44(11%) positive for both prim-
ers (1BCC,3SCC,1PCIS). 17/44(39%) MCV +ve samples were HIV+ve with 4/17(23%) MCVPS1 
+ve, 16/17(94%) MCVPyV +ve and 3/17(18%) MCVPS1 and MCVPyV +ve (1BCC,1SCC,1PCIS). 
6/17(35%) were co-infected with HPV:- 1BCC (HPV 24), 1BCC (HPV 11, 2, 7), 1Penile SCC (HPV 
11), 1CIS (HPV 45, 25, 96), 1BCC (HPV 9), 1PCIS (HPV 11). 27/44(61%) MCV +ve samples were 
HIV-ve with 4/27(15%) MCVPS1 +ve, 25/27(93%) MCPyV+ve and 2/27(7%) MCVPS1 and MCVPyV 
+ve (2SCC). 10/27(37%) were co-infected with HPV:- 1BCC/1SCC (HPV 18), 1AK/1SCC (HPV 1), 
1AK/1SCC (HPV 92),1BCC (HPV 80),1CIS/1 BCC (HPV 11),1PCIS (HPV 16). This is the largest 
study of MCV in NMSC/pre-cancer in HIV+ve and -ve patients. We have previously shown HPV is 
highly prevalent in NMSC/pre-cancer and MCV also appears to be prevalent. 61% MCV+ve cases 
were HIV-ve, suggesting having HIV may not increase the risk of MCV infection. Overall, 16/44 
(36%) MCV+ve cases were HPV co-infected with no difference between HIV+ve/-ve groups. The 
detection of MCV in NMSC may simply be an incidental finding, but if MCV and HPV are factors 
in NMSC pathogenesis, they may work independently.    
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HUMIRA Improves Health-Related Quality of Life (HRQoL) in Patients with Moderate to 
Severe Hidradenitis Suppurativa (HS): Results from the First 12 Weeks of PIONEER I
A Armstrong,1 B Pinsky,2 M Sundaram,2 Y Gu,2 D Williams2 and Y Bao2 1 University of 
Colorado Denver, School of Medicine, Denver, CO and 2 AbbVie Inc, North Chicago, IL
HS is an inflammatory skin disease characterized by recurrent, painful abscesses and nodules 
that may lead to physical debilitation and psychological strain. Currently there are no approved 
pharmaceutical treatments for HS. PIONEER I is a phase 3 clinical trial to evaluate the safety and 
efficacy of adalimumab (ADA) vs placebo (PBO) in patients (pts) with moderate to severe HS. The 
current study focused on the first 12-week, double-blind, PBO-controlled period (Period A). In 
Period A, pts were randomized 1:1 to ADA (160 mg at week 0; 80 mg at week 2; 40 mg weekly 
from week 4) or matching PBO. At baseline, pts had a diagnosis of HS for ≥1 year, a total abscess 
and inflammatory nodule count ≥3, HS lesions in ≥2 body areas, Hurley Stage II or III, and were 
anti-tumor necrosis factor–naïve. Change from baseline to week 12 in 4 HRQoL outcomes (Short 
Form [SF]-36, Dermatology Life Quality Index [DLQI], and HS-related skin pain based on a numeric 
rating scale) was examined. Higher scores on the SF-36 and lower scores on DLQI and skin pain 
indicate less impairment. At baseline the disease burden of HS had a large impact on the HRQoL 
scores (mean DLQI >15, and all SF-36 domains under 44). By the end of Period A, ADA pts reported 
significantly greater improvements vs PBO in the physical aspects of SF-36: physical component 
summary score (4.2 vs 1.5; p=0.005), role physical (4.5 vs 2.2; p=0.039), bodily pain (4.9 vs 2.4; 
p=0.018), and general health (3.0 vs -0.4; p<0.002). In addition, ADA pts had a significantly larger 
improvement in skin-specific HRQoL (DLQI: 5.4 vs 2.9; p<0.001). Finally, HS-related skin pain at 
its worst for pts receiving ADA was reduced by 19.6% compared with 6.5% (p=0.016) with PBO. 
In conclusion, ADA pts had significantly greater improvements in the physical aspects of the SF-36, 
DLQI, and HS-related skin pain compared with PBO pts.    
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Immunoadsorption in Bullous Pemphigoid
F Schulze,1 M Kasperkiewicz,1 S Süfke,2 D Zillikens1 and E Schmidt1 1 Department 
of Dermatology, University Hospital of Schleswig-Holstein, Lübeck, Germany and 2 
Department of Nephrology, University Hospital of Schleswig-Holstein, Lübeck, Germany
Immunoadsorption (IA) is increasingly used for treatment of pemphigus. IA has also been successfully 
applied in pemphigoid diseases, characterized by subepidermal blistering due to autoantibodies 
directed against structural proteins of the dermal-epidermal junction. However, information on the 
use of IA in bullous pemphigoid (BP), the most frequent pemphigoid disease, is limited. Here, we 
report on 15 patients with severe or relapsed BP (mean age 79 year; range 56 to 94 years) treated 
by adjuvant IA on 3 consecutive days in addition to tapering doses of oral prednisolone, dapsone, 
and lesional topical clobetasol propionate 0.05%. We observed rapid clinical responses (complete 
remission on therapy) in 7 patients (46%) within 4 weeks after initiation of the protocol. Serum auto-
antibodies decreased by 78% and 93% within 1 and 3 months, respectively. Within the follow-up 
period of between 1 and 57 months (mean 19,5 months) reversible anaemia in 7 of the 15 patients 
(46%) was the most common adverse event, most likely attributed to concomitant dapsone, while 
no IA-related adverse events were noted. Our observations show that the application of IA in the 
elderly patient population with severe and/or therapy-refractory BP in addition to a standard therapy 
regimen is a feasible and safe treatment option.    
199
Impaired incretin effect is an early sign of dysmetabolism in non-diabetic patients with 
psoriasis 
M Gyldenløve,1 T Vilsbøll,2 JJ Holst,3 FK Knop2 and L Skov1 1 Department of Dermato-
Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, 2 Department 
of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark and 3 
Department of Biomedicine, NNF Centre for Basic Metabolic Research, University of 
Copenhagen, Copenhagen, Denmark
Psoriasis is associated with increased risk of type 2 diabetes, but the underlying pathophysiology 
remains largely unknown. The gastrointestinal system plays a major role in the development of type 
2 diabetes. The impact of psoriasis on gut factors involved in glucose metabolism has not previously 
been examined. In this study, we aimed to investigate if non-obese, non-diabetic patients with 
psoriasis exhibit impaired incretin effect and/or gastrointestinal-mediated glucose disposal. A three 
hour 50-gram oral glucose tolerance test (OGTT) and an isoglycemic intravenous glucose infusion 
(IIGI) were performed in 12 patients with moderate, untreated psoriasis and 12 healthy controls 
matched for age, gender, and body mass index. All subjects had normal glucose tolerance and no 
genetic dispositions to diabetes. Glucose, insulin, and C-peptide levels were measured repeatedly. 
The incretin effect and GIGD were calculated based on insulin responses and amounts of glucose uti-
lised, respectively. The patients with psoriasis exhibited significantly impaired incretin effect (38.5% 
vs. 56.5%, P=0.021) and gastrointestinal-mediated glucose disposal compared to healthy controls 
(52.5% vs. 60.9%, P=0.038). OGTT and IIGI blood glucose excursions were significantly higher 
in the psoriasis group (P<0.036). These novel findings suggest that gut-related pathophysiologic 
mechanisms may underlie the increased susceptibility for type 2 diabetes in patients with psoriasis.   
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In vitro and in vivo efficacy of a new complex on acne pathogenesis: the P. acnes case
S Trompezinski,1 S Weber,1 B Cadars,2 F Larue,1 N Ardiet,1 M Chavagnac-Bonneville,2 
M Sayag2 and E Jourdan2 1 NAOS Group Research, Aix-en-Provence, France and 2 
Laboratoire Bioderma, Lyon, France
Acne is a common multifactorial inflammatory dermatosis of the pilosebaceous unit in which sebum 
and the bacterium Propionibacterium acnes play an important role. P. acnes secretes protopor-
phyrins and lipases that generate pro-inflammatory lipids, leading to the formation of comedones 
and localized inflammatory reactions. The aim of these studies was to evaluate the effects of a 
complex termed BGM on P. acnes colonization and on the inflammation it induces. BGM complex 
is composed of backuchiol, gingko biloba extract and mannitol. For clinical or ex vivo studies, 
BGM complex was included in a cosmetic formulation. Determination of Minimum Inhibitory 
Concentration (MIC) of BGM complex against P. acnes was determined using a standard method. 
Additionally, P. acnes colonization on skin face was analyzed by measuring porphyrin fluorescence 
(VISIA CAS system) on 20 acneic volunteers using the BGM complex formulation twice a day during 
56 days. To evaluate anti-inflammatory effect, human skin explants were treated with BGM complex 
or vehicle during 3 days before skin incubation with P. acnes. IL-8 and TNFα were quantified by 
ELISA method in supernatants of skin explants. It was shown in vitro that BGM complex has potent 
antibacterial properties on P. acnes. In vivo, daily application of a formulation containing BGM 
complex on the face significantly reduced porphyrin production by P. acnes after 28 and 56 days 
of use. These results are correlated to a decrease of P. acnes on face skin. In a skin explant model, 
BGM complex significantly reduced TNFα and IL-8 synthesis induced by P. acnes and involved 
in the inflammatory reaction of acne. BGM complex inhibits P. acnes proliferation and reduces 
inflammation. By acting on P. acnes, BGM complex provides an efficient care of acne.    
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Increased iron levels in aged skin lead to increased ferritin expression and higher ROS-levels 
after irradiation
T Bussmann, K Reimann and H Reuter General Skin Care, Beiersdorf AG, Hamburg, Germany
Iron is essential for cell growth and many metabolic processes, but it is also toxic and involved in 
the generation of reactive oxygen free radicals via Fenton and Haber Weiss reaction. Tight regu-
lation of iron stores by e.g. desquamation or menstruation usually prevents iron accumulation in 
the human body. The purpose of our study is to examine the changes in iron level and metabolism 
during aging of human skin. Here, we present the effect of iron loading on the ferritin expression 
and the generation of reactive oxygen species (ROS) in human dermal fibroblast. Additionally, we 
firstly showed the accumulation of iron in the dermis of aged female human dermis. We used a cell 
culture model for the determination of the accumulation of iron in human dermal fibroblasts and 
used this system for the analysis of the effect of iron on the cells. Moreover, we examined dermal 
samples from young (22.7 ± 4.4 (mean age ± SD); n = 14) and old (60.8 ± 7.0 (mean age ± SD); 
n = 14) women to analyze iron in vivo. In cell culture, ferritin light chain as well as ferritin heavy 
chain was induced by the treatment with ferrous ions. Thus, the cell avoids the toxic effect of an 
iron accumulation by binding of the iron to ferritin and by that keeping the iron in a redox inactive 
state. However, the irradiation of iron treated cells with solar simulated radiation leads to a strong 
increase in ROS levels. This results from the release of protein-bound iron and the possibility of 
ferrous ions to react with oxygen species. The analysis of skin samples by a photometric iron assay 
reveals an increase in non-heme iron concentration in the dermis of aged donors. Furthermore, 
ferritin, aconitase and haptoglobin were identified to be increased by aging. The in vivo results in 
combination with the findings in the cell culture model support our hypothesis of a direct connection 
between higher ROS levels in aged dermis and the accumulation of iron. These findings lead to new 
possibilities for the repression of light-induced ROS-generation in old skin by iron chelating agents.   
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Independent association of neutrophil counts and PASI under TNF-α antagonist treatment. A 
retrospective study investigating differential effects of Adalimumab, Etanercept, and Usteki-
numab on inflammatory biomarkers and autoantibodies.
J Hoffmann, C Knoop, AH Enk (ESDR) and EN Hadaschik Dermatology, University of 
Heidelberg, Heidelberg, Germany
TNF-α inhibitors Adalimumab and Etanercept, and IL12/IL23 antagonist Ustekinumab are used to 
treat psoriasis and psoriasis-arthritis. General alterations of inflammatory biomarkers under treatment 
with these biologics have been reported, a detailed description of parameter dynamics and a cor-
relation to treatment response is, however, lacking. Here, we present a retrospective data analysis 
of 113 patients with psoriasis receiving Adalimumab, 64 psoriasis patients receiving Etanercept, and 
23 patients receiving Ustekinumab. Anti-nuclear antibody (ANA) titers, anti-doublestranded-DNA 
(anti-dsDNA) concentrations, polymorphonuclear cell (PMN) counts, Non-PMN leucocyte counts, 
C-reactive protein (CRP) concentrations and PASI values at baseline and during treatment were 
recovered. ANA-titers and anti-dsDNA concentrations significantly increased under treatment with. 
PMN counts considerably decreased under treatment with Adalimumab and Etanercept and, to a 
lesser extent, under treatment with Ustekinumab. Interestingly, statistical analysis using general-
ized estimating equations revealed a positive association of PASI-values and neutrophil counts, 
but not Non-PMN leucocyte counts, in patients treated with Adalimumab and, to a lesser extent, 
Etanercept, that was independent of treatment duration and CRP. The role of PMN in psoriasis 
pathogenesis has recently received much attention. Histologically, numbers of PMN in psoriatic 
lesions vary depending on disease state and individual patient. The present data illustrates differ-
ential effects of biologics on inflammatory biomarkers, particularly PMN counts, and supports the 
role of neutrophil granulocytes as relevant targets of immunosuppressive treatments in psoriasis. 
One may speculate that these effects contribute to the differential therapeutic efficacy of treatments 
observed in individual patients.    
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Laser therapy for ocular lesions of nevus of Ota
S Amaki,3 M Kobayashi1 and M Tanaka2 1 Plastic Surgery, Amaki Clinic, Tokyo, Japan, 2 
Dermatology, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan and 3 
Ophthalmology, Amaki Clinic, Tokyo, Japan
Laser therapy for cutaneous lesion of nevus of Ota is already established, however therapy for 
ocular lesion has not been reported. The purpose of this study is to validate the efficacy and 
safety of Q-switched Nd: YAG laser therapy for ocular lesion of nevus of Ota. 15 eyes from 13 
patients were treated by Tango (Ellex) at SLT mode (wave length: 532 nm, diameter: 400 mm, laser 
irradiation time: 3 nsec). An informed consent was obtained from all the patients. The cases were 
selected under the condition that the patients were treated more than three times and followed-up 
three times or more. 3 male and 10 female patients from the age of 19 to 52 (average: 29.5) were 
enrolled in the study. All the cases were with cutaneous and ocular (sclera) lesion. Irradiation output 
was 0.8 to 1.5 mJ and a treatment was with irradiation of 10 to 663 shots. Improvements were 
evaluated objectively by SA and subjectively by the patients at each treatment. The ocular lesions 
on the sclera were responded well to a treatment and tended to improve with each treatment when 
the photographs were compared by SA. Subjective improvements by the patients were also noted 
after three treatments. Complete disappearance was achieved at 12 eyes and an improvement was 
confirmed at 3 eyes. Conjunctival edema and mild subconjunctival haemorrhage had occurred in 
all the cases, of which the former subsided in a few days and the latter disappeared in two weeks. 
There was no recurrence or serious complication in the period of observation. Superficial lesions 
seemed to improve but deep lesions did not seem to respond the treatment. Unresponsiveness of 
the deep lesion might be rather a benefit of the treatment because it means there is no intraocular 
damage. The Q-switched Nd: YAG laser has been found to be effective and safe therapy for ocular 
(sclera) lesions of nevus of Ota.    
204
Lysine and arginine based surfactants and their potential use in dermatology and cosmetology
M Dawgul,1 K Greber,1 S Bartoszewska,1 W Baranska-Rybak,2 W Sawicki1 and W Kamysz1 
1 Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland and 2 Faculty of 
Medicine, Medical University of Gdansk, Gdansk, Poland
Short cationic lipopeptides were designed in order to imitate the properties of endogenous anti-
microbial peptides. The obtained compounds proved to be effective antibiofilm agents towards 
clinical isolates of Staphylococcus aureus (SA) in our previous study. However due to the haemolytic 
activity their use in antimicrobial therapy is limited. In the present work lipopeptides: C16-KK-NH2, 
C16-KK-NH2, C16-KKK-NH2, C16-KRK-NH2, C16-RR-NH2, C16-RRR-NH2 were obtained via chemical 
synthesis. Their antimicrobial activity against reference strains of bacteria and fungi as well as 
toxicity towards human HaCaT keratinocytes were assessed. Tested lipopeptides exhibited activity 
against all tested microorganisms. However the compounds proved to be toxic towards HaCaT 
cells in their microbiologically active concentrations. Lipopeptides did not permeate through syn-
thetic membranes what allows to expect lack of penetration through human skin. Therefore their 
application on the intact skin (e.g. for eradication of SA carriage) is considered. We have found that 
no resistance to lipopeptides was developed after consecutive passages of SA clinical isolates in 
medium supplemented with tested compounds, while significant decrease of activity of mupirocin 
and fusidic acid was observed. Broad spectrum of antimicrobial activity and low risk of resistance 
development suggests potential application of lipopeptides as future preservatives. Moreover the 
surface-active properties of tested compounds were confirmed using semiautomatic tensiometer. 
Obtained results suggest that short lipopeptides could simultaneously fulfil the roles of the preserva-
tive and the surface-active agent. Our next step are maintenance, emulsyfing and skin irritation tests.   
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Modulating effect of a new biofunctional on skin photo-aging: in vivo studies conducted 
on Asian skin 
R Zhao,2 X Qu,2 M Ling,2 G Oberto,1 Y Ferreira,1 K Cucumel1 and N Domloge1 1 Ashland 
Specialty Ingredients, Sophia Antipolis, France and 2 Ashland Specialty Ingredients, Shanghai, 
China
The signs of age (wrinkles, age spots) are aggravated by external stresses such as long exposure to 
solar radiation or cold stresses. To limit the damage, the skin possesses highly conserved proteins in 
the mitochondria, mitochondrial Heat Shock Proteins (mtHSPs), which help to preserve functional 
proteins and cellular homeostasis during heat shock, and CIRBP proteins (Cold-Inducible RNA-Bind-
ing Protein) in response to cold stress. The aim of our study was to evaluate the activity of an artemia 
extract on the skin appearance related to aging (wrinkles and skin tone) during winter. The study 
was carried out on 39 Asian volunteers (30 to 65 year-old) for an eight-week period. Volunteers 
applied the extract and the placebo on their face twice a day. The appearance of wrinkles was 
evaluated by Visioline® VL650 and Visia-CR® pictures. The skin tone and spot appearance were 
assessed by Mexameter® MX18 measurements and by photoMAX® pro at different time points. 
Since the first week of application, a decrease in the total wrinkle area was observed on the extract 
treated-sides compared to the placebo sides. After 28 days of treatment with the extract, all the 
wrinkle parameters were significantly reduced compared to placebo. These beneficial effects on 
appearance of wrinkles were maintained until the end of the study.Furthermore, the skin and of the 
age spots color continuously declined from the first week of the study to the end, for the biofunctional 
treated-sides compared to the placebo treated-sides. At all time points, the tone difference between 
the two treated sides was statistically significant for the measurements done on the skin and on 
an age spot. All these in vivo studies indicated that the positive modulation of the extract helped 
decrease the appearance of skin wrinkles as well as improving skin complexion.    
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Neurotic chronic dermatological patients employ task- and emotion-focused coping with 
stress and present lower self-efficacy. 
A Platkowska, A Ograczyk, A Skrzypczak, A Kepska and A Zalewska-Janowska 
Psychodermatology Department, Medical University of Lodz, Lodz, Poland
Psychological aspects plays an important role in therapy of chronic skin diseases. The aim of the 
study was to evaluate selected psychological parameters- coping with stress, self-efficacy and per-
sonality traits in dermatological out-patients. The study was performed at the general practitioner 
office. The group consisted of 84 patients (56 women, 28 men) aged 18-60 years, suffering from 
chronic dermatological diseases (contact eczema, seborrheic dermatitis, acne vulgaris, urticaria, 
psoriasis vulgaris). The following questionnaires were used: our socio-demographic questionnaire, 
INTE questionnaire by Shutter et al (Polish adaptation by Ciechanowicz et al) evaluating emotional 
intelligence, GSES Generalized Self-Efficacy Scale by Schwarzer and Jerusalem (Polish adaptation 
by Juczyski), CISS Coping with stress strategies by Endler et al (Polish adaptation by Szczepaniak 
et al). Statistical analysis was performed by STATISTICA and p≤0,05 was considered statistically 
significant. We found positive correlation between neuroticism and emotion-focused coping (r= 
0.63, p<0.0001);extraversion and avoidance-focused coping (r=0.24, p=0.05); extraversion and 
distracting coping (r=0.48, p<0.0001); agreeableness and task-orientated coping (r=0.22, p= 0.05); 
agreeableness with distracting coping (r=0.33, p<0.0001); conscientiousness and task-orientated 
coping (r=0.39, p<0.0001). We observed negative correlations between neuroticism and task-fo-
cused coping (r= -0.24, p=0.05) and agreeableness with indulging in social contacts (r=-0.27, 
p=0.05) in our group of patients. In conclusion, identification of neurotic chronic skin diseases 
patients should alert every medical health practitioner to employ a more specific care focused on 
emotional aspects of the disease and strengthening of patients` self- efficacy.    
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New biomarkers for disease severity in atopic dermatitis
JL Thijs,1 S Nierkens,2 B Giovannone,1 C Bruijnzeel-Koomen,1 M de Bruin-Weller1 and 
D Hijnen1 1 Dermatology/Allergology, Univeristy Medical Center Utrecht, Utrecht, 
Netherlands and 2 U-DAIR and Laboratory of Translational Immunology, University Medical 
Center Utrecht, Utrecht, Netherlands
Promising new treatments for atopic dermatitis (AD) are currently investigated. However, compar-
ing the results of different trials in AD is difficult because of the large number of different clinical 
outcome measures that have been used. Therefore, there is an urgent need for valid, reliable and 
objective severity measures of AD that allow comparison of clinical trials and epidemiological stud-
ies. A great variety of serum biomarkers for disease severity in AD has been reported. Correlations 
between these biomarkers and disease severity showed large differences between publications. This 
was a pilot study in which we used a multiplex (Luminex®) approach we investigated 31 potential 
biomarkers for AD in sera from 17 adult patients diagnosed with severe AD. Blood was taken at 
admission to the hospital and after two weeks of treatment. Patients were treated with potent topical 
corticosteroids. Severity of AD at the time of blood sampling was assessed by using the Six Area Six 
Sign Atopic Dermatitis (SASSAD). All patients showed significant clinical improvement. SASSAD 
scores decreased from 36.9 at baseline to 8.0 after two weeks of treatment. Biomarker levels at 
admission and after treatment were compared to determine if they are associated to disease severity. 
Of the 31 markers studied, seven showed a statistically significantly decrease after treatment and 
are therefore associated with SASSAD. This included TARC, MDC, interleukin 22, PARC, soluble 
interleukin-2 receptor, E-selectin and interleukin 16. Using stepwise regression analysis with cross 
validation, we found a combination of biomarkers (n=4) that shows a strong correlation to disease 
severity (r2=0.856). In this pilot study we show that a combination of biomarkers shows a stronger 
correlation to disease severity, compared to a single biomarker. We suggest to use this set of bio-
markers for monitoring disease severity in future clinical studies to improve study comparability.   
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Objective analysis of poly-L-lactic acid (PLLA) injection efficacy in different setting
S Byun,1 J Shin,1 S Kwon,1 K Seo,2 M Park,1 J Lee,3 K Park,1 J Na1 and C Huh1 1 Dermatology, 
Seoul National University College of Medicine, Seoul National University Bundang Hospital, 
Seongnam-si, Gyeonggi-do, Republic of Korea, 2 Dermatology, Modelo Clinic, Seoul, 
Republic of Korea and 3 College of Medicine, Emory University, Atlanta, GA
A Poly-L-lactic acid (PLLA) is a soft tissue filler known to stimulate collagen production. The purpose 
of this study is to analyze objective volumetric effect of PLLA in different setting of injection schedule 
on the cheek, which was not evaluated yet. A split-face, evaluator-blind randomized study in 24 
volunteers was conducted. One side was injected 3 times with dose of 4cc per visit at week 0, 4, and 
8, and the other side was injected 2 times with dose of 6cc per visit at week 4 and 8, respectively. 
Volunteers were evaluated with facial volume loss scale (FVLS) from 1 to 5(most severe) according 
to volume loss severity and objective volumetric values using Vectra-CR 3D camera system. Mea-
sured average FVLS in 3 times injection side were 2.43 (Before), 1.91 (1 month), 1.37 (3 months), 
1.27 (6 months), and 1.23 (12 months), respectively. In 2 times injection side, measured average 
values were 2.31 (Before), 1.73 (1 month), 1.30 (3 months), 1.12 (6 months), and 1.13 (12 months), 
respectively. Improvement of FVLS was statistically significant (p<0.05) and maintained until 12 
months in both injection side. Vectra showed volumetric difference (cc) between before and after 
injection. In 3 times injection side, it was increased from 2.12cc (after 1 month) to 3.17cc (after 
12 months). In 2 times injection side, it was increased from 2.26cc (after 1 month) to 3.19cc (after 
12 months). Gradual volumetric improvement over 12 months was statistically significant in both 
sides (P<0.05, generalized linear model). There was not statistically significant difference between 
three and two times injection side in both FVLS and Vectra. There was no severe adverse event. In 
conclusion, PLLA filler has continuous volumetric effect and there was not a significant difference 
by injection times at the same total injection volume.    
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Probiotic strain Lactobacillus paracasei CNCM I-2116 decreases skin reactivity
A Gueniche,1 D Philippe,2 M Renouf,2 I Castiel,1 L Breton1 and B Jalil2 1 Loreal research 
innovation, Asnieres sur Seine, France and 2 Nestle research, Lausanne, Switzerland
Reactive skin is characterized by a marked sensitivity of the skin to external stimuli and impaired skin 
barrier repair ability. Probiotics are defined as live microorganisms that when ingested in sufficient 
amount positively balance the host microbiota and beneficially improve health. Beyond the effect 
on the intestinal microbiota, some probiotic strains display potent immune-modulatory properties 
including at the skin level. Indeed, we have previously shown in ex vivo and preclinical studies 
and for the first time in a randomized placebo-controlled trial that oral supplementation with a 
probiotic beneficially impacted skin sensitivity and barrier function. The aim of this study was to 
confirm the efficacy on skin reactivity. For that purpose, Lactobacillus paracasei CNCM I2116 was 
tested in a randomized double-blind vehicle-controlled trial. 66 female volunteers with reactive 
skin received probiotics vs. placebo powders suspended in drinking water at a daily dose of 109 
CFU for two months period. Skin reactivy as assessed by capsaicin test and skin barrier function 
recovery. These evaluations were performed at initiation (day1) and at the end of the supplemen-
tation (day57). The results showed that the volunteers who received L. paracasei CNCM I-2116 
presented a significant decrease in skin sensitivity over the treatment period. Moreover the barrier 
function recovery, following tape-stripping disruption, was significantly faster for the volunteers 
having received L. paracasei CNCM I-2116 compared to the volunteers taking placebo powder. 
The results of the study confirm that oral supplementation with the probiotic L. paracasei CNCM 
I-2116 has a beneficial effect on reactive skin and underline that the efficacy is maintained with 
a lower dose (i.e. 109 CFU as compared to the first study in which 1010 was tested). Overall these 
findings support new strategies based on a nutritional approach for the treatment and/or prevention 
of the symptoms related to reactive skin.    
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Safety and Efficacy of Adalimumab in Patients with Moderate to Severe Hidradenitis Sup-
purativa: Results from First 12 Weeks of PIONEER I, a Phase 3, Randomized, Placebo-Con-
trolled Trial 
A Kimball,1 CC Zouboulis,2 AW Armstrong,3 N Korman,4 JJ Crowley,5 C Lynde,6 K Belknap,7 
Y Gu7 and DA Williams7 1 Harvard Medical School, Boston, MA, 2 Dessau Medical Center, 
Dessau, Germany, 3 University of Colorado, Denver, CO, 4 University Hospitals Case 
Medical Center, Cleveland, OH, 5 Bakersfield Dermatology, Bakersfield, CA, 6 The Lynde 
Centre for Dermatology, Markham, ON, Canada and 7 AbbVie Inc., North Chicago, IL
This multicenter study evaluated safety and efficacy of adalimumab (ADA) in patients (pts) with mod-
erate to severe hidradenitis suppurativa (HS). The 12-wk double-blind, placebo (PBO)-controlled 
period is reported here. Anti-TNFα-naïve pts diagnosed with HS for ≥1 year, with total abscess and 
inflammatory nodule (AN) count of ≥3 and HS lesions in ≥2 body areas (Hurley Stage II or III), were 
randomized 1:1 to ADA (160mg at wk0; 80mg at wk2; 40mg weekly from wk4) or matching PBO. 
Efficacy was analyzed for all randomized pts (intent-to-treat [ITT]), and safety for all ITT pts who 
received at least 1 dose of study drug. Non-responder imputation was used for missing data. The 307 
ITT pts (63.8% female, 76.2% white, 20.2% black) had mean age of 37.0 years, mean HS duration 
of 11.5 years, and median AN count of 11. A significantly higher proportion of pts randomized to 
ADA achieved the primary efficacy endpoint HiSCR (Hidradenitis Suppurativa Clinical Response 
defined as ≥50% reduction from baseline in AN count with no increase in abscess or draining fistula 
counts) at wk12; ADA (64/153, 41.8%) vs PBO (40/154, 26.0%; p=0.003). Adverse events (AE) 
reported by >10% of pts were exacerbation of HS (13.2% PBO, 9.2% ADA) and nasopharyngitis 
(10.5% PBO, 5.9% ADA). Cellulitis was reported by 2 pts for each PBO and ADA. Serious AEs 
included pyelonephritis (n=1 ADA) and breast cancer (n=1 PBO). No deaths occurred. In PIONEER 
I, a Phase 3 randomized PBO-controlled study of ADA in HS, significantly more pts randomized 
to ADA achieved HiSCR vs pts randomized to PBO. AEs were comparable to PBO and consistent 
with the ADA safety profile; no new risks were identified.    
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Safety and Efficacy of AN2728 Topical Ointment, 2% and 0.5% in Adolescents with Atopic 
Dermatitis
L Stein-Gold,2 L Spelman,3 M Spellman,1 M Hughes1 and L Zane1 1 Clinical Research and 
Development, Anacor Pharmaceuticals, Inc, Palo Alto, CA, 2 Henry Ford Hospital, Detroit, 
MI and 3 Queensland Institute of Dermatology, Holland Park, QLD, Australia
AN2728 is an oxaborole compound and phosphodiesterase-4 inhibitor. A dose-ranging study was 
conducted to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, 
administered once daily (QD) or twice daily (BID), in the treatment of mild-to-moderate atopic der-
matitis (AD) in adolescents. This multi-center, randomized, double-blind, phase 2 study enrolled 86 
patients aged 12-17 years with AD involving up to 35% of body surface area. Enrolled patients had 
two target lesions of similar severity based on AD severity index (ADSI) score of 6-12, a maximum 
1-point difference in ADSI score between the two lesions, and an erythema subscore of at least 2 
(moderate). The index scores ranged from 0 (none) to 3 (severe) for erythema, pruritus, exudation, 
excoriation, and lichenification. Patients were randomly assigned to QD or BID treatment. Patients 
treated one target lesion with AN2728 Topical Ointment, 2% and the other with AN2728 Topical 
Ointment, 0.5%. Disease severity was determined based on ADSI scores on days 8, 15, 22 and 29. 
The primary endpoint was the change from baseline in ADSI score. AN2728 Topical Ointment, 
2% and 0.5%, were found to be generally safe and well-tolerated. No serious adverse events (AEs) 
were reported, and no treatment discontinuation occurred due to AEs. Application site symptoms 
were uncommon. The greatest improvement in ADSI score was noted with AN2728 Topical Oint-
ment, 2% BID, yielding a 71% improvement in ADSI score from baseline after 28 days, with 62% 
of lesions achieving total or partial clearance. This treatment group also demonstrated the greatest 
improvement across all five signs and symptoms of AD after 28 days, including a 79% reduction in 
pruritus severity. Of the four dosing regimens examined in this Phase 2 study of adolescents with 
AD, AN2728 Topical Ointment, 2% BID produced the greatest improvements in disease severity 
and was generally safe and well tolerated.    
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Stress parameters in chronic urticaria patients
A Zalewska-Janowska,3 J Miniszewska,2 M Kozlowska,1 A Kaszuba1 and A Ograczyk3 1 
Department of Dermatology and Pediatric Dermatology, Medical University of Lodz, Lodz, 
Poland, 2 University of Lodz, Lodz, Poland and 3 Psychodermatology Department, Medical 
University of Lodz, Lodz, Poland
Nowadays the important role of stress in chronic urticaria course and exacerbation is marked. Stress 
can be estimated on the basis of psychological methods (questionnaires) and objective markers 
(cortisol and DHEA-S levels). The study objective was to compare the stress parameters between 
group of chronic urticaria patients and healthy control group and to investigate the relation between 
subjective and objective stress parameters. The study group consisted of 30 chronic urticaria patients 
(age M=47.4, SD=13.92) and 30 healthy controls (age M=47.1, SD=14.22). All involved subjects 
were women. Laboratory methods (Enzyme-linked immunosorbent assay ELISA test) were used to 
mark cortisol and DHEA-S levels. Psychological questionnaires Social Readjustement Rating Scale 
(SRRS, Holmes, Rahe) and Perceived Stress Scale (PSS-10, Cohen, Kamarck, Mermelstein) were 
applied to assess subjectively experienced stress level. The statistical significance was set at 0.05. 
The comparison of cortisol to DHEA-S ratio in patients and healthy controls manifested the statisti-
cally significant differences indicating higher objective stress level in urticaria ones (p<0.001). The 
analogical relation was observed in case of subjectively experienced stress between both groups 
(p<0.001). In patients group the association between perceived stress and the amount of stressful 
life events was presented (r=0.47, p=0.01). The link between objective and subjective stress param-
eters was not observed. The conducted study indicated the stress importance in course of chronic 
urticaria. No link between psychological questionnaires results and cortisol/DHEA-S ratio marked 
the role of subjectively perceived stress. Based on the obtained results, it is worth employing stress 
coping interventions for urticaria patients to reduce their discomfort.    
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Survival analysis in AML patients with leukemia cutis
SJ Divito,2 C Joyce,1 RL Lin2 and AP Saavedra2 1 Tulane University, New Orleans, LA and 2 
Harvard Medical School, Boston, MA
Leukemia cutis refers to skin infiltration by lymphoid or myeloid malignant cells, and is considered a 
poor prognostic factor in patients with hematologic malignancy. However, studies of the disease are 
limited, especially over the past decade despite major advancements in chemotherapeutics and stem 
cell transplantation. We hypothesized that leukemia cutis is not a poor prognostic factor in AML. 
To study this, we performed a retrospective study of patients ≥ 18 years old with histopathologic 
diagnosis of leukemia cutis over 12 years at Brigham and Women’s Hospital/Dana Farber Cancer 
Institute. We identified 51 patients with acute myelogenous leukemia (AML) with leukemia cutis. 
Duration of survival for all AML patients with leukemia cutis was 22 months, with absolute survival 
rate of 36% and 24% at 1- and 5-years, respectively, comparable to the current national 5-year 
survival rate in AML of 24.9%. Survival in leukemia cutis patients varied with type of AML. Further, 
leukemia cutis patients who were treated with stem cell transplantation had significantly prolonged 
survival of mean duration 44 months, with absolute 1- and 5-year survival rates of 69 and 46%, 
respectively, compared to only 7 months mean survival, and 1- and 5-year survival rates of 10 and 
0%, respectively, in non-transplanted patients with leukemia cutis. In conclusion, our data suggests 
that leukemia cutis may not be the poor prognostic factor that it was previously thought to be and 
stem cell transplantation can lead to improved survival in this patient population.    
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The altered distribution of dendritic cells in the inflamed skin lesion of various nutritional 
deficiencies
S Yamaguchi,1 N Kanazawa,6 Y Sogabe,2 M Yasuda,2 S Izaki,4 A Utani,5 Y Narisawa,3 
H Uezato1 and K Takahashi1 1 Dermatology, Graduate School of Medicine, University of 
the Ryukyus, Nishihara-cho, Japan, 2 Dermatology, Gunma University,, Maebashi, Japan, 
3 Dermatology, Saga University, Saga, Japan, 4 Dermatology, Saitama Medical University 
Saitama Medical Center, Saitama, Japan, 5 Nagasaki University, Nagasaki, Japan and 6 
Wakayama Medical University, Wakayama, Japan
Nutritional deficiencies cause pellagra (nicotinic acid deficiency), biotin deficiency, acrodermatitis 
enteropathica (Zn deficiency), necrolytic migratory erythema (aminoacid deficiency). These patients 
commonly present with similar skin dermatosis and show shared histological alterations, including 
vacuolization and necrosis of keratinocytes in the upper epidermis. We previously reported the 
complete depletion of Langerhans cells in human pellagra and biotin deficiency patients. We further 
conducted to determine the distributions of dendritic cells and other cutaneous cells in skin lesions 
of patients with acrodermatitis enteropathica, necrolytic migratory erythema those additionally 
show the shared histological alterations with pellagra and biotin deficiency. Six pellagra and one 
biotin-deficiency, one acrodermatitis enteropathica, three necrolytic migratory erythema as well as 
eleven healthy individuals those served as controls were included. We found Langerhans cells were 
substantially decreased or eventually disappeared in skin lesion of all observed diseases. In con-
trast, CD1c+ dendritic cells were correspondingly disappeared in the dermis of moderate to severe 
pellagra and biotin deficient patients. Meanwhile, in skin lesions of acrodermatitis enteropathica 
and necrolytic migratory erythema, CD1c+ were not at all affected. CD14+ dendritic cells were 
increased in the dermis of all observed diseases compared to non-inflamed healthy skin, however, 
there was no apparent difference of CD14+ dendritic cells induction among these trophic diseases. 
Our observations suggest that the susceptibility to nutrients varies among the cutaneous dendritic 
cells, and the origin of these dendritic cells likewise differs with each.    
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The effects of listening to classical music on saliva stress parameters in psoriasis in-patients 
O Heringa,1 W Owczarek,2 M Kozlowska,3 A Ograczyk1 and AM Zalewska1 1 
Psychodermatology, Medical University of Łód, Łód, Poland, 2 Dermatology, Military Institute 
of Medicine, Warsaw, Poland and 3 Dermatology, The Dermatology, Pediatric Dermatology 
and Oncology Clinic, Łód, Poland
The purpose of this study was to evaluate the effects of classical music on selected psychological and 
physiological stress parameters in psoriasis in-patients. Hospitalised psoriasis patients were subjected 
to psychological and physiological sets of measurement during two days (first day no classical music 
vs. second day classical music). Four psychological questionnaires measuring depression (Beck’s 
Depression Inventory), quality of life (Skindex-29), stress (Rahe & Holmes Stress Inventory) and 
anxiety (STAI) were used. Saliva samples measuring cortisol and dehydroepiandrosteron-sulphate 
concentrations (using ELISA) were collected. A total of 12 saliva samples per patient, divided in 
two sets (no music and preselected classical music) were taken. Moreover, each set was performed 
three times (morning, afternoon, evening), where two saliva samples were used to compare before 
and after listening to music. Based on saliva measurements, a statistical difference after listening 
to 30 min of classical music was found ( cortisol p=0.038, mean=3.1, SD= 6.2). There also was 
a statistical significant result between the control and experimental group ( DHEA-S p= 0.002, 
mean= -7,2, SD= 8.2). Additionally, increases in DHEA-S levels during the experimental day were 
observed. In conclusion, listening to classical music might be an additional technique to look at 
when treating psoriasis patients.    
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The efficacy and safety of cryo fat reduction in the treatment of pseudogynecomastia
C Huh, J Shin, S Kwon, K Park and J Na Dermatology, Seoul National University College of 
Medicine and Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea
Pseudogynecomastia is a condition of enlarged male breast primarily due to the accumulation of 
adipose tissue. Treatment options for this condition are limited including weight reduction and 
surgical liposuction. Cryo fat reduction provides noninvasive, selective, localized subcutaneous 
adipocyte destruction without epidermal or dermal injury by inducing selective adipocyte apoptosis. 
This study was designed to evaluate the efficacy of cryo fat reduction in the treatment of pseudogy-
necomastia. In this prospective, 28-week trial, 12 male volunteers with psudogynecomastia were 
treated with cryo fat reduction twice bimonthly. Efficacy was determined by breast circumference 
measurement, ultrasonographic measurement of subcutaneous layer thickness, physician’s global 
photographic assessment, and patient’s satisfaction at baseline, week 4, week 8, week 16, and 
week 28. Safety was evaluated by questionnaire at each visit. In 11 subjects who completed the 
trial, breast circumference and thickness of fat layer decreased significantly at week 8, and were 
gradually reduced until week 28. Physician’s photographic assessment and patient’s satisfaction 
showed significant improvement at each visit. Although some volunteers appealed transient pain 
or bruise after treatment, there was no serious adverse event. In conclusion, cryo fat reduction is a 
safe and effective therapeutic option of the treatment of pseudogynecomastia.    
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The potential role of substance P antagonist in the treatment of atopic dermatitis 
L Lönndahl,2 K Nordlind1 and M Holst3 1 Dep of medicine, Karolinska Institutet, Stockholm, 
Sweden, 2 Dep of medicine, Karolinska Institutet, Stockholm, Sweden and 3 Dep of Woman 
and Child Health, Karolinska Institutet, Stockholm, Sweden
Atopic dermatitis (AD) is an often severely itching, chronic, inflammatory skin disorder and may 
worsen due to stress and anxiety. Tachykinins have been suggested to influence the level of inflam-
mation as well as being involved in pruritus, stress and anxiety. Aprepitant is an antagonist for the 
NK-1 receptor of substance P. Patients with moderate-severe AD have been recruited to an open 
randomized trial, in which we compare the effect of Aprepitant to a standard topical treatment. 
Adult patients with AD (n=13) received 80 mg Aprepitant daily in 7 days as supplement to a 
standard topical treatment with a moderately strong steroid and a moisturizer (n=13). The control 
group of adult patients with AD (n=16) received only topical treatment. The patients have been 
monitored regarding extent of the disease (SCORAD), degree of pruritus (VAS) and scratching. In the 
group treated by Aprepitant the SCORAD decreased from 44.0±11.5 to 34.6, VAS from 5.5±1.6 to 
3.2±2.3 and scratching movements from 82.6±113.9 to 54.3±74.6. In the control group SCORAD 
decreased from 36.7±11.4 to 27.5±15.7, VAS from 6.5±2.3 to 4.6±2.7 and scratching movements 
from 44.3±38.2 to 29.5±37.4. At three days there was a high tendency (p=0.07) for a VAS value 
reduction in the group treated by Aprepitant. There were few side effects. Aprepitant may be used 
in the treatment of atopic dermatitis.    
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The role of PPARγ modulation in the control of insulin and IGF-1 induced sebogenesis and 
inflammation in vitro
A Mastrofrancesco,1 M Ottaviani,1 G Cardinali,1 M Ludovici,1 S Briganti,1 C Zouboulis,2 
V Lora,1 E Camera1 and M Picardo1 1 S Gallicano Dermatologic Institute, Rome, Italy and 
2 Departments of Dermatology, Venereology, Allergology, and Immunology,, Dessau, 
Germany
One of the current hypotheses of acne pathogenesis suggests that dietary glicemic load predispose 
to dysregulation of the sebaceous gland activity, leading to altered sebum secretion. By contrast, 
low glycemic load diet seems to ameliorate clinical manifestations of acne. Triggers of insulin/
insulin-like growth factor-1 (IGF-1) signalling are key stimuli for the sebaceous gland functions. In 
sebocytes, insulin/IGF-1 signaling activates PI3K/Akt pathway that, in turns, induces the expression 
of SREBP-1 resulting in enhanced sebogenesis. The nuclear receptor peroxisome proliferators-ac-
tivated receptor-γ (PPARγ) is pivotal in lipid and glucose metabolisms, and in the modulation of 
inflammatory pathways. Thus, we investigated the role PPARγ plays in the sebaceous lipid synthesis 
and cytokines expression induced by insulin/IGF-1 in sebocyte cell line SZ95 using a specific PPARγ 
modulator (GMG-43AC). GC-MS analysis of fatty acids (FA) demonstrated that GMG-43AC inhibited 
the insulin/IGF-1 induced lipid synthesis up to 50 % depending on the specific FA. Up to 2-fold 
reduction of insulin/IGF-1 induced SREBP-1 mRNA level and its target genes, such as FAS, SCD-1, 
HMG-CoAR, and FADS-2 was observed upon GMG-43AC treatment. Consistently, the insulin/IGF-1 
activated PI3K/Akt pathway was down-modulated by GMG-43AC. In addition, we observed that 
insulin/IGF-1 induced a significant up-regulation of IL-1, IL-6, and IL-8. Modulating PPARγ activity 
proved to contrast the pro-inflammatory effects of insulin/IGF-1. In particular, the up-regulation of 
IL-6 and IL-8 was completely abrogated by GMG-43AC. The specific PPARγ inhibitor GW9662 
abolished the GMG-43AC effect on the lipogenic and inflammatory genes confirming that both 
phenomena are under the control of PPARγ. In conclusion our results highlighted the ability of PPARγ 
to control sebogenesis and inflammation mediated by lipogenic stimuli offering the possibility for 
a new therapeutic target.    
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Topical application of baby- and adult-aloe on ultraviolet B irradiated mouse skin with metab-
olite profiling based biomarker discovery
H Park,1 E Moon,2 S Lee,1 S Kim,2 S Do,3 J Kim,3 K Liu4 and C Lee1 1 Department of 
Bioscience and Biotechnology, Konkuk University, Seoul, Republic of Korea, 2 College of 
Pharmacy, Gachon University, Incheon, Republic of Korea, 3 Life Science Research Institute, 
Univera Inc., Seoul, Republic of Korea and 4 College of Pharmacy and Research Institute of 
Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea
Topical application with two different sized-aloe extracts, baby aloe shoot (immature aloe with <10 
cm) and adult aloe (mature aloe with >50 cm), suppressed ultraviolet (UV) B-induced skin damages 
including increased epidermal thickness and matrix metallopreteinase-1 expression, decreased 
procollagen type I and involucrin expressions, and the change of collagen fiber. Additionally, 
we revealed that many different kinds of skin metabolites, such as amino acids, organic acids, 
nucleobases, fatty acids, sterols, carbohydrates, and glycerophospholipids, were altered by topical 
application with adult aloe and baby aloe shoot extracts in epidermal and dermal layer from UVB-ex-
posed skin using mass spectrometry (MS)-based techniques with multivariate statistical analysis. 
Especially, four nucleobases (hypoxanthine, uridine, inosine and cytidine) and cholesterol were 
specifically influenced by adult aloe and baby aloe shoot treatment, respectively. The alterations in 
skin metabolites generated by applying aloe extracts on UVB-induced skin were generally greater 
in epidermis than in dermis of the skin. These data demonstrated that these metabolites could be 
potential biomarkers to explain the effects of aloe extracts on UVB-irradiated skin. Our results 
suggested that topical application with aloe extracts was efficient at restoring the changes of skin 
conditions and skin metabolites caused by UVB irradiation.    
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Topical Clobetasolpropionat has no Influence on Inflammation or Efficacy after Ingenol 
Mebutate Treatment of Grade I-III Actinic Keratoses 
AM Erlendsson,1 KE Karmisholt,1 CS Haak,1 IM Stender2 and M Haedersdal1 1 Department 
of Dermatology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, 
Denmark and 2 Hudklinikken Jaegersborg Alle, Copenhagen, Denmark
Topical Ingenol mebutate (IngMeb) is approved for field treatment of actinic keratosis (AK). The 
treatment causes transient and potentially severe inflammation that can be discomforting to patients. 
In this study we investigated if local skin responses (LSR) generated by IngMeb can be reduced 
with a topical glucocorticosteroid and its possible impact on treatment efficacy. In a blinded, 
randomized clinical study, patients with grade I, II, and III AKs on face or scalp were treated in two 
25 cm2 symmetrical fields with IngMeb (0.015%) once daily for three consecutive days. Following 
IngMeb treatment one field was randomly assigned to application of topical clobetasolpropionat 
(CP) (0.05%) twice daily for four days. Skin response was evaluated on day 1, 4, 8, 15 and 57 on 
an LSR scale ranging from 0-24 with higher numbers indicating more severe reactions. Clearance 
of lesions was evaluated after two weeks and two months. A total of 21 patients with a median of 
16 AKs per treatment field (range 8-27) were included in the study. No difference in LSR-score was 
found between IngMeb treatment, and IngMeb followed by CP (LSR on day 8: 7 vs. 6; p = 0.93). 
Skin response peaked on day four (LSR 10) and returned to baseline values on day 15 (LSR 2). 
CP-application had no effect on treatment efficacy. At two-month follow-up, overall lesion clearance 
was 86% (86% IngMeb vs. 86% IngMeb+CP) and when stratified for AK-grade, clearance rates were 
88% (grade I AK), 70% (grade II), and 60% (grade III). In conclusion, application of a topical gluco-
corticosteroid after IngMeb does not influence locals skin response or treatment efficacy. Overall, 
IngMeb clears over 85% of treated lesions and shows a therapeutic effect on all AK severity-grades.   
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Topical penetration of clobetasol-17-propionate into psoriatic lesional and non-lesional skin 
illustrated with time and space resolution by dermal open flow microperfusion 
M Bodenlenz,1 C Dragatin,1 K Benkali,2 T Augustin,1 C Hoefferer,1 P Martel,2 F Rony,2 
TR Pieber,3 N Wagner2 and F Sinner1 1 HEALTH, Joanneum Research Forschungsgesellschaft 
mbH, Graz, Austria, 2 Galderma R&D, Sophia Antipolis, France and 3 Department of 
Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, 
Graz, Austria
The hyperkeratosed stratum corneum in psoriasis has been reported to act as trap compartment 
for topical drugs which was not predicted by an in vitro and a clinical study on healthy skin. We 
aimed to elaborate on the role of the stratum corneum for topical penetration by continuous in 
vivo monitoring of the intradermal concentrations of clobetasol-17-propionate (CP-17) in psoriatic 
lesions and non-lesional skin following single and repeated topical dosing of 0.05% CP-17 cream. 
Twelve patients received Dermoval® cream on lesional and non-lesional skin once daily for 14 
days. On day 1 and day 14 dermal Open Flow Microperfusion (dOFM) probes were implanted into 
the dermis for continuous collection of dermal interstitial fluid samples for 24 h post-dose. Probe 
depth was measured by 50 MHz ultrasound and CP-17 was analyzed in dOFM samples by LC-MS/
MS. AUCs 0-24h were analyzed in a mixed-effects model to identify the determinant variables. 
dOFM sampling succeeded to provide intradermal CP-17 concentration profiles for 24 h following 
topical doses of normal strength. Mixed-effects model analyses identified (i) skin site (lesional/
non-lesional), (ii) the time (day 1/day 14), as well as (iii) probe depth as variables that determine 
AUC 0-24h. Consequently CP-17 AUCs were plotted as function of depth showing decreased AUCs 
in lesional vs. non-lesional psoriatic skin and higher dermal AUCs after repeated application due 
to faster penetration. This dOFM study sheds light on the penetration of a typical lipophilic topical 
drug into lesional and non-lesional skin, and supports the role of the stratum corneum in psoriasis 
acting as trap compartment for lipophilic drugs. dOFM is suitable for lipophilic sampling and delivers 
pharmacokinetic data with time and space resolution.    
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Tyrosine kinase inhibitors exert inhibitory effects on vitamin D3 metabolism 
LM Mehlig,2 C Garve,2 A Wiedenfeld,2 JT Tauer,1 M Suttorp,1 S Beissert2 and A Bauer2 
1 Department of Pediatrics, Division of Pediatric Hematology and Oncology, University 
Hospital “Carl Gustav Carus”, TU Dresden, Dresden, Germany and 2 Department of 
Dermatology, University Hospital “Carl Gustav Carus”, TU Dresden, Dresden, Germany
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by a hybrid gene and 
its upregulated activity of the tyrosine kinase (TK) BCR-ABL1. TK inhibitors like imatinib (IMA) or 
nilotinib (NIL) inhibit this TK and have therefore changed the therapy of CML dramatically. However, 
IMA and NIL exert “off target” side effects on bone metabolism in adult and pediatric patients. As 
vitamin D3 is involved in the complex cycle of bone remodelling, we investigated the influence of 
IMA and NIL on the vitamin D3 metabolism in HaCaT cells. Therefore, cells were incubated with 
25 mM 7-dehydrocholesterole and exposed to UVB. Starting with the beginning of irradiation cells 
were incubated with 1 mM TKI for 24 hours, 48 hours or 72 hours, respectively. Calcidiol and 
calcitriol levels were determined quantitatively using commercial enzyme assays. To analyze if the 
VD3 processing cytochrome P450 isoenzymes CYP2R1, CYP27A1 and CYP27B1 were inhibited by 
TKI, specific inhibitors were applied concomittantly. In vitro at the clinically effective concentra-
tion both TKIs tested significantly impaired production of calcidiol and calcitriol. IMA incubation 
resulted to calcitriol levels of about 50% while NIL levels decreased to 10 % in comparison to 
controls without TKI. Additionally, interaction studies performed with inhibitors of P450 enzyme 
family (VID400, ketoconazole) in the absence of IMA revealed unchanged calcidiol levels (range: 
90 – 110 ng/1*106 cells) while calcitriol levels decreased to 60 % of control values. Adding IMA 
in the presence of VID400 resulted in increased calcidiol levels by 600 % but unchanged calcitriol 
synthesis. Treatment with ketoconazole and IMA revealed increased calcitriol levels by 200 %. This 
point to interferences of IMA and NIL with the vitamin D3 cascade due to its metabolization by 
CYP27B1 and led to detailed studies about appropriate compensation strategies.    
      
